Published in final edited form as:

World J Surg. 2000 July ; 24(7): 759–782.

History of Clinical Transplantation

Thomas E. Starzl, M.D., Ph.D.

Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Falk Clinic,
4th Floor, 3601 Fifth Avenue, Pittsburgh, Pennsylvania 15213, USA

Abstract

The emergence of transplantation has seen the development of increasingly potent immunosuppressive agents, progressively better methods of tissue and organ preservation, refinements in histocompatibility matching, and numerous innovations in surgical techniques. Such efforts in combination ultimately made it possible to successfully engraft all of the organs and bone marrow cells in humans. At a more fundamental level, however, the transplantation enterprise hinged on two seminal turning points. The first was the recognition by Billingham, Brent, and Medawar in 1953 that it was possible to induce chimerism-associated neonatal tolerance deliberately. This discovery escalated over the next 15 years to the first successful bone marrow transplantations in humans in 1968. The second turning point was the demonstration during the early 1960s that canine and human organ allografts could self-induce tolerance with the aid of immunosuppression. By the end of 1962, however, it had been incorrectly concluded that turning points one and two involved different immune mechanisms. The error was not corrected until well into the 1990s. In this historical account, the vast literature that sprang up during the intervening 30 years has been summarized. Although admirably documenting empiric progress in clinical transplantation, its failure to explain organ allograft acceptance predestined organ recipients to lifetime immunosuppression and precluded fundamental changes in the treatment policies. After it was discovered in 1992 that long-surviving organ transplant recipients had persistent microchimerism, it was possible to see the mechanistic commonality of organ and bone marrow transplantation. A clarifying central principle of immunology could then be synthesized with which to guide efforts to induce tolerance systematically to human tissues and perhaps ultimately to xenografts.

How transplantation came to be a clinical discipline can be pieced together by perusing two volumes of reminiscences collected by Paul I. Terasaki during 1991–1992 from many of the persons who were directly involved. One volume was devoted to the discovery of the major histocompatibility complex (MHC), with particular reference to the human leukocyte antigens (HLA) that are widely used today for tissue matching [1]. The other focused on milestones in the development of clinical transplantation [2]. All of the contributions described in both volumes can be traced back in one way or other to the demonstration more than a half century ago by Peter Brian Medawar that the rejection of allografts is an immunologic phenomenon [3, 4].

Ten years later (1953) Billingham, Brent, and Medawar [5] showed that tolerance to skin allografts could be induced by inoculating fetal or prenatal mice with immunocompetent spleen cells from adult donors. Because of their immunologic immaturity, the recipients were incapable of rejecting the spleen cells whose progeny survived indefinitely. Specific nonresponsiveness to donor strain tissues was retained as the recipient animals grew to adult life, whereas normal reactivity evolved to third party grafts and other kinds of antigens.

This was not the first demonstration that tolerance could be deliberately produced. Analogous to the neonatal transplant model, Traub [6] showed in 1936 that the lymphocytic choriomeningitis virus (LCMV) persisted after transplacental infection of the embryo from the mother or, alternatively, by injection into newborn mice. However, when the mice were infected as adults, the virus was eliminated immunologically. Similar observations had been made in experimental tumor models. Murphy [7] reported in 1912 the outgrowth of Rous chicken sarcoma cells on the chorioallantoic membranes of duck or pigeon egg embryos, which could be reversed by inoculation of adult chicken lymphoid cells [8], whereas sarcoma implantation into adults was not possible.

The observations of Murphy and Traub did not influence the early development of transplantation. Instead, the impetus and rationale for the experiments of Billingham et al. [5, 9] and similar ones in chickens by Hasek [10] originated with Owen [11], who demonstrated that freemartin cattle [the calf equivalent of human fraternal (dizygotic) twins] became permanent hematopoietic chimeras if fusion of their placentas existed in utero, allowing fetal cross-circulation (Fig. 1); such animals permanently accept each other's skin [12]. Burnet and Fenner [14] predicted that this natural chimerism and tolerance to other donor tissues and organs could be induced by the kind of experiments successfully performed by Billingham et al. However, Billingham and Brent [15, 16] soon learned in mice, parallel with similar observations by Simonsen [17] in chickens, that the penalty for infusing immuno-competent hematopoietic cells was graft-versus-host disease (GVHD) unless there was a close genetic relationship (i.e., histocompatibility) between the donor and recipient.

This was the beginning of modern transplantation immunology, an extensive history of which has been written by Brent [18], one of its principal architects. Each cell- and organ-defined branch of transplantation also has had its historians, who have described the stages through which specific procedures moved to the bedside from experimental laboratories—or in some cases directly. The culminating clinical events can be capsulized with a list of the first successful allotransplantation in humans of the kidney [19], liver [20], heart [21, 22], lung [23], pancreas [24], intestine [25], multiple abdominal viscera [26], and bone marrow [27–30].

Although such milestones and dozens of lesser ones are important, the emphasis in this account is on developments that were applicable to all varieties of allografts and responsible for major transitions in transplantation ideology. It becomes apparent as the layers of history are peeled away that there were only two seminal turning points in the evolution of clinical transplantation. One was the induction of chimerism-associated neonatal tolerance by Billingham, Brent, and Medawar in 1953. The second was the demonstration during 1962–1963 that organ allografts could self-induce tolerance with the aid of immunosuppression [31]. All subsequent developments in organ transplantation depended on exploitation of this principle, using variations of the drug strategy that had made its discovery possible. Ironically, the down side of the resulting revolution in organ transplantation was the early introduction of a conceptual error that distorted the maturation of transplantation immunology and adversely affected the orderly development of general immunology.

The error, which was not corrected until well into the 1990s [32–34], was the conclusion by consensus that organ allograft acceptance involved mechanisms different from the chimerism-dependent ones of neonatal tolerance and its clinical analogue bone marrow transplantation. Consequently, the vast literature that sprang up during the intervening 30 years admirably documented the progression of improvements in clinical transplantation while failing to explain what was being accomplished [35]. Therefore the reader may profit by skipping to the last section of this article (Allograft Acceptance versus Acquired

Tolerance) before attempting to understand what went on between 1963 and 1993 and before.

Prehistory: Before Immunosuppression

An indelible mark on the pages of transplantation history was left with the perfection of techniques for organ revascularization using surgical anastomosis by Alexis Carrel at the beginning of the twentieth century [36]. Aside from the technical contributions, which provided the foundation for conventional vascular surgery, Carrel recognized that transplanted organ allografts were not permanently accepted, although he did not know why.

Using vascular surgical techniques, animal research on transplantation was most highly focused on the kidney for most of the next half century [37–39]. The extrarenal vacuum rapidly was filled between 1958 and 1960 with the development in several laboratories of canine models with which to study all of the intraabdominal organs [40–44] and thoracic organs [45–47]. Although each organ presented specific technical and physiologic issues, the core problems of immunosuppression, tissue matching, and allograft preservation eventually were worked out mainly with the kidney and liver and applied to other organs with minor modifications.

Hetero (Xeno) Transplantation

The first known attempts at clinical renal transplantation by vascular anastomoses were made between the beginning of the twentieth century and 1923 in France [48], Germany [49], and elsewhere (summarized in [50]) using pig, sheep, goat, and subhuman primate donors. None of the kidneys functioned for long, if at all; and the human recipients died a few hours to 9 days later. No further animal-to-human transplantations were tried again until 1963, after immunosuppression was available [51, 52].

Homo (Allo) Transplantation

In 1936 Voronoy of Kiev, Russia, reported the transplantation of a kidney from a cadaver donor of B⁺ blood type to a recipient of O⁺ blood type [53], in violation of what have become accepted rules of tissue transfer [54, 55] (Table 1). In addition, the allograft was jeopardized by the residual risk of acute mercury poisoning (from a suicide attempt), which had caused the recipient's renal failure. A final adverse factor was the 6-hour lapse between the donor's death and organ procurement. The allograft did not produce any urine during the 48 hours of the patient's posttransplant survival. Although other attempts may have been made by Voronoy [56], another 15 years passed before significant kidney transplant activities were resumed in France.

In 1952 Rene Kuss [57] and Charles Dubost [58] in Paris and Marceau Servelle [59] in Creteil carried out a series of renal transplantations with kidneys removed from convict donors immediately after their execution by guillotine. The next year, the French nephrologist Jean Hamburger, in collaboration with urologist Louis Michon at the Hôpital Necker in Paris, reported a mother-to-son transplantation of a kidney that functioned well for 3 weeks before being rejected [60]. The procedure developed by Kuss and the other French surgeons and used for this first live donor kidney transplantation has been performed hundreds of thousands of times since then. The operation's relative freedom from chronic morbidity would soon be demonstrated with the identical (monozygotic) twin transplantations of Joseph E. Murray and John Merrill and their associates [61] at the Peter Bent Brigham Hospital in Boston.

The efforts by the French teams were widely known, and visitors flocked to Paris during the early 1950s to learn first-hand from the experience. One of the observers of the

extraperitoneal pelvic operation (often called the Kuss procedure in Europe) was John Merrill, as Hume and Merrill et al. [62] described in their account of the first clinical trials at the Peter Bent Brigham Hospital. Among Hume's nine Boston cases, however, all but one of the allografts were placed in the recipient thigh, revascularized from the femoral vessels, and provided with urinary drainage by skin ureterostomies.

The exceptional case in the Boston series [62] was the first one. The donor and recipient operations were performed in Springfield, Massachusetts, on March 30, 1951, by L.H. Doolittle. The donor kidney, excised because of a carcinoma of the lower ureter, was implanted in the vacated renal fossa of the recipient after removing the native organ. The recipient patient had been under short-term dialysis care at the Brigham, where the first artificial kidney in the United States had been brought from Holland by Wilhelm Kolff and modified by Harvard engineers, as described in detail by Moore [63].

The next eight operations, in which the allografts were placed in the anterior thigh, were performed by Hume in Boston between April 23, 1951, and December 3, 1952. The report of the nine cases stands as one of the medical classics of the twentieth century, providing an extensive clinical and pathologic profile of renal allograft rejection in untreated human recipients. The descriptions complemented the report of Michon and Hamburger of the live-donor French case (see earlier [60]) and pathfinding studies in dogs by Morten Simonsen in Denmark [38] and of W. James Dempster in England [39]. It is noteworthy that Hume treated some of his patients with adrenal cortical steroids. It was already known from experimental studies that steroid therapy modestly mitigated primary skin graft rejection [64–66] and even slowed the accelerated rejection of presensitized recipients [67].

Although compilation of the Boston series postdated the early French efforts (as generously annotated by Hume), the commitment of the Harvard group to transplantation was evident long before the availability of effective immunosuppression. Hume, who moved in 1956 from Boston to the Medical College of Virginia (Richmond), remained a major force in transplantation until his death in the crash of a private plane (of which he was the pilot) near Los Angeles in May 1973. His friend and colleague, John Merrill, who remained in Boston, drowned off the beach of a Caribbean island in 1984.

None of the European and American efforts to this time, or all together, would have had any lasting impact on medical practice were it not for what lay ahead. The principal ingredients of organ transplantation—immunosuppression, tissue matching, organ procurement (and preservation)—were still unknown or undeveloped. The only unequivocal example of clinically significant allograft function through 1954 was provided by one of the nonimmunosuppressed patients of Hume et al. [62] whose thigh kidney produced life-supporting urine output for 5 months. Similar claims about function of an allograft transplanted to the orthotopic location [68] (i.e., as in Doolittle's case [62]) or to a non-anatomic site [69] were considered implausible by later critics.

The existence of these cases was public knowledge, but the failure of all the grafts (usually with death of the patient) left little room for optimism. The perception, if not the reality, of hopelessness was changed at the Peter Bent Brigham Hospital 2 days before Christmas 1954 when a kidney was removed from a healthy man by urologist J. Hartwell Harrison and transplanted by Joseph E. Murray to the pelvic location of the donor's uremic, identical twin brother [61, 70]. Although no effort was made to preserve the isograft, it functioned promptly despite 82 minutes of warm ischemia. The recipient lived for nearly 25 years before dying of atherosclerotic coronary artery disease.

According to Merrill et al. [61], exploitation of genetic identity for whole organ transplantation had been suggested by the recipient's physician, David C. Miller, of the

Public Health Service Hospital, Boston. It already was well known that identical twins did not reject each others' skin grafts [71]. To ensure identity, reciprocal skin grafting was performed in the Boston twins. Although the identical twin cases attracted worldwide attention, organ transplantation now had reached a dead end. Further progress in the presence of an immunologic barrier would require effective immunosuppression. The possibility of meeting this objective could only be regarded as bleak. To understand why, it is necessary to appreciate not only how barren the landscape of immunology was but also how slowly the preexisting information had been filled in.

A century had passed between the first vaccination procedure in 1796 (Edward Jenner, small pox) and confirmation of the immunization principle by Louis Pasteur (with chicken cholera and rabies). The proof obtained by Robert Koch that microorganisms caused anthrax (1876) and subsequently many other infectious diseases stimulated a search for the host's protective mechanisms. This search yielded components of the immune response: antibodies [Emil Adolf Von Behring and Shibasaburo Kitasato (1890)], immune cells [Ilya Metchnikoff (1884)], and complement [Jules Bordet (1895)]. In addition, Paul Erlich developed the side chain theory (1890), according to which each cell has a vital center of protein substance and a series of side chains (later known as receptors) to which toxic substances and nutrients were absorbed and then assimilated. In 1910 Erlich introduced the first antimicrobial drug, an arsenical compound effective against syphilis, yaws, and several other infections.

Decades passed between the cluster of great contributions at the turn of the twentieth century and the proposal by F. McFarlane Burnet that antibodies were produced in each individual only to those antigens to which he or she was exposed [14]. The lack of major movement between events is evident from a list of Nobel Prizes [72] (Table 2). Although 6 of the first 17 Nobel laureates (1901–1919) were honored for work relevant to immunology/transplantation, there was only one more example (Karl Landsteiner, ABO blood groups) among the next 57 (1920–1959). Beginning with Burnet and Medawar (see above), 17 of the 77 laureates since 1960 have been directly responsible for, contributed to, or directly benefited from, advances in transplantation (Table 2).

In Burnet's original hypothesis of immunity, antibody synthesis was postulated to occur after an antigen locked onto a membrane-bound receptor (a version of the antibody) displayed at the surface of an immune cell. After binding the antibody, the cell proliferated, producing a clone that secreted identical antibodies (the clonal selection theory). Nossal subsequently proved that the clone rose from a single cell ("one cell/one antibody") [75]. Although Burnet's hypothesis was not yet complete, it was to become the cornerstone of modern immunology.

Concept of Immunosuppression

With Recipient Cytoablation

The transition of tissue and organ transplantation from an exercise in futility to tenuous practicality involved a surprisingly small number of advances, which were interspersed over long periods of frustration. After Medawar's demonstration in 1944 that rejection was an immunologic event [3, 4], a logical and inevitable question was: Why not protect the organ allograft by weakening the immune system? This idea was tested in rabbits during 1950–1951 with cortisone [64, 65] and total body irradiation [76]. Both techniques prolonged skin graft survival for only a few days.

Neither these results, nor those reported with cortisone in 1952 by Cannon and Longmire [66] in a chicken skin graft model generated much optimism. However, the Cannon–Longmire report contained three observations that, in retrospect, presaged not only the

acquired neonatal tolerance produced by Billingham, Brent, and Medawar the following year but also the most important clinical advances in transplantation of the succeeding decades. First, skin grafts exchanged between 1-day-old chicks of different breeds had a high rate of initial engraftment and a 6% incidence of permanent take. Second, the window of neonatal opportunity was gone by 4 days. Third, and most important, the percent of permanent engraftment of neonatally transplanted skin was increased to more than 20% by a course of cortisone, with no increase of mortality.

The significance of the third observation was recognized by Cannon and Longmire who wrote: “Although the cortisone did not entirely prevent a reaction in the homograft, it did decrease the incidence of reaction. Even more important, the increased incidence of reaction [sic] free grafts appeared to maintain itself after the drug was discontinued. This phenomenon is one which up to the present time has not been found in homograft experiments on mammals and humans.”

Despite a confirmatory follow-up study in 1957 [77], the neglected Cannon–Longmire article faded quickly from the collective memory of both basic scientists and clinicians. In contrast, the achievement of acquired neonatal tolerance by Billingham et al. in 1953 [5, 9] ignited interest in transplantation as never before. Two years later, Main and Prehn [78] attempted to simulate in adult mice the environment that allowed the acquisition of neonatal tolerance. The three steps were (1) to cripple the immune system with supralethal total body irradiation (TBI); (2) to replace it with allogeneic bone marrow (producing a hematolymphopoietic chimera); and (3) to engraft skin from the same inbred strain as the donor of the bone marrow.

The experiments were successful [79, 80]; but as with the neonatal tolerance model, lethal GVHD could be avoided only when there were “weak” histocompatibility barriers. Applying the chimerism strategy for kidney transplantation in beagle dogs in Cooperstown, New York, Mannick et al. [80] reported good renal allograft function in a supralethally irradiated recipient, which also was given donor bone marrow and was a hematolymphopoietic chimera; the animal lived for 73 days before dying of pneumonia. Because it was demonstrated later that this outcome depended on the identity of the dog lymphocyte antigens (DLA) [81, 82], an accidental DLA match was suspected in retrospect to have been present in Mannick’s experiment. Efforts by Hume et al. [83] and subsequently by Rapaport et al. [84] and others to broaden the range of acceptable histocompatibility inevitably led to lethal GVHD, rejection, or both.

Bone Marrow Transplantation—With the impasse, workers in bone marrow and whole organ transplantation took separate pathways. Bone marrow transplantation was dependent a priori on the classic chimerism-associated acquired tolerance induction defined at the outset by Billingham, Brent, and Medawar in the neonatal model. Despite the fact that only highly histocompatible donors could be used, clinical success with bone marrow engraftment was achieved in 1963 by Mathe et al. in Paris [27], whose patient lived for 2 years with chronic GVHD before committing suicide.

Five years later, Gatti and Good et al. in Minneapolis [29] and Bach et al. at the University of Wisconsin [28] each transplanted bone marrow to recipients who are well today. The lifetime efforts of Thomas [30], van Bekkum [85], and others fueled the maturation of bone marrow transplantation into accepted clinical therapy for numerous hematologic diseases (including malignancies), acquired immune deficiency disorders, mesenchymally based inborn errors of metabolism, and an assortment of other indications.

Bone marrow transplantation was an intellectual triumph. Its development could be traced in a straight line back to the experiments of Main and Prehn [78] and before that to the acquired neonatal tolerance of Billingham, Brent, and Medawar [5, 9] and the natural tolerance of Owen's freemartin cattle [11].

Whole Organ Transplantation—In contrast, clinical organ transplantation, the wide clinical use of which preceded bone marrow transplantation by a decade, appeared to be disconnected from a rational base when it was concluded that organ engraftment seemingly was independent of chimerism. An extension of the Main–Prehn strategy (i.e., lethal TBI followed by bone marrow and kidney allografts, as in Mannick's dog) was used by Murray et al. [86] in only two cases, both in 1958. The next 10 kidney recipients in Boston were conditioned with *sublethal TBI without bone marrow* [19, 86, 87]. Eleven of the twelve irradiated patients died after 0 to 28 days.

The survivor (who was not given bone marrow) had adequate renal function from the time his fraternal twin brother's kidney was transplanted on January 24, 1959 until he died in July 1979 (Table 3). With this historical accomplishment, the genetic barrier to organ transplantation had been definitively breached for the first time in any species [19]. Five months later Hamburger et al. [88] added a second fraternal twin transplantation, using the same treatment (Table 3). This second recipient had good renal function until his death 26 years later from carcinoma of the urinary bladder.

In these two dizygotic twin cases, it was conceivable that the donor and recipient placentas had fused during gestation, analogous to Owen's freemartin cattle (see above and Figure 1). This suspicion was put to rest at the Paris centers of Jean Hamburger [89] and Rene Kuss [90] by four more examples during 1960–1962 of survival of more than 1 year. In Kuss's two cases the donors were not related (Table 3). During the critical period from January 1959 through the spring of 1962, the cumulative French experience was the principal (and perhaps the only) justification to continue clinical trials in kidney transplantation.

The experience from Boston and Paris summarized in Table 3 showed that bone marrow infusion was not a necessary condition for prolonged survival of kidney allografts and ostensibly eliminated the requirement of chimerism. The stage was set for drug therapy. In fact, both Hamburger and Kuss mentioned the use of adrenal cortical steroids as an adjunct to TBI (Table 3); but neither the dose nor the indication for the steroids was described. In addition, Kuss secondarily administered 6-mercaptopurine (6-MP) to one of his cytoablated patients as early as August 1960 [90], "on the basis of the recent results of the experimental studies conducted by Calne" [91] (see also next section). Calne had made an invited visit to the Paris center a few months earlier (R. Kuss and R. Calne, personal communication).

Some authorities have considered irradiation-induced and drug-induced graft acceptance to be different phenomena [50, 87, 92]. More recently, it has become obvious that the variable degrees of graft acceptance achieved with sublethal TBI between January 1959 and February 1962 were fundamentally the same as that seen in tens of thousands of drug-treated humans following transplantation of various whole organs (see Allograft Acceptance versus Acquired Tolerance).

With Drug Immunosuppression

After it was learned that TBI alone could result in prolongation of kidney allografts, it was logical to focus the search for immuno-suppressive drugs on myelotoxic agents whose effects mimicked those of irradiation. In September 1960 Willard Goodwin of Los Angeles produced severe bone marrow depression with metho-trexate and cyclophosphamide in a young female recipient of her mother's kidney. The patient subsequently developed multiple

rejections that were associated with bone marrow recovery. They were temporarily reversed with prednisone several times during the 143 days of survival. It was the first example of protracted human kidney allograft function with drug treatment alone [93]. However, the case was not reported until 1963.

Kidney transplant surgeons were quick to realize that bone marrow depression should be avoided, not deliberately imposed, following the demonstration by Schwartz and Dameschek [94] that 6-MP in a nontransplant rabbit model was immunosuppressive in submyelotoxic doses. Within a few months after their seminal discovery, Schwartz and Dameschek [95] and Meeker [96] (working with Condie, Weiner, Varco, and Good) showed that 6-MP caused a dose-related delay of skin graft rejection in rabbits. Aware of these results but independent of each other, Calne [97] in London and Zukoski, Lee, and Hume [98] in Richmond, Virginia, demonstrated the same thing in the canine kidney transplant model. In June 1960 Calne moved from the Royal Free Hospital to join Murray at the Peter Bent Brigham Hospital (Boston) for further preclinical studies of 6-MP and its analogue azathioprine [87, 99–101].

The two drugs had been developed originally by Gertrude Elion and George Hitchings as antileukemia agents [102]. Their possible use for transplantation was greeted at first with feverish enthusiasm because it was generally conceded that recipient cytoablation would permit success in only occasional cases of human renal transplantation. Although approximately 95% of the mongrel canine kidney recipients treated with 6-MP or azathioprine died within less than 100 days from rejection or infection, occasional examples were recorded of long-term or seemingly permanent allograft acceptance [103–106] following discontinuance of a 4- to 12-month course of immunosuppression. The number of these animals was discouragingly small, but it was an accomplishment never remotely approached using TBI, with or without adjunct bone marrow. Survival of Mannick's single cytoablated animal for 73 days after combined bone marrow and kidney transplantation had been the previous high water mark in dogs (see earlier [80]).

The survival of some of Calne's animals beyond 6 months led to the decision at the Brigham to begin clinical trials with chemical immunosuppression. However, the poor therapeutic margin of the 6-MP and azathioprine when used alone in dogs was recognized. Calne and Murray also were forewarned by an earlier clinical experience of Hopewell, Calne, and Beswick [107], which was not published until 1964, in which 6-MP had been used to treat three kidney recipients (including one with a living donor) during 1959–1960; all three recipients had died.

Consequently, the canine studies of 6-MP and azathioprine in Boston were highly focused on finding more effective drug combinations [87, 99, 101, 108]. Although adrenal cortical steroids were tested, they did not appear to potentiate the value of azathioprine [99, 101], prompting Murray in his clinical trial to opt for adjunct cytotoxic agents such as azaserine and actinomycin C [87]. Only one of the first 10 kidney recipients treated with either 6-MP ($n = 2$) or azathioprine-based immunosuppression ($n = 8$) survived more than 6 months (the last one in Table 3) [87, 111].

At the nadir of the resulting pessimism, two reproducible observations, first in dogs and then in humans, were made at the University of Colorado. Taken together, these findings profoundly shaped future developments in transplantation of all organs and eventually of bone marrow. The observations were encapsulated in the title of a report published in October 1963: "The Reversal of Rejection in Human Renal Homografts with the Subsequent Development of Homograft Tolerance" [31].

The reversal was readily accomplished by temporarily adding unprecedented high doses of prednisone (200 mg/day) to baseline immunosuppression with azathioprine. The evidence that the living donor kidneys had self-induced tolerance under an umbrella of immunosuppression was equally clear. Most of the recipients had a subsequent progressively diminishing need for immunosuppression, usually to doses lower than those that initially failed to prevent rejection. The tolerance was complete enough to allow the patients to go home to an unrestricted environment. Nine of the first ten of these kidney recipients achieved prolonged graft survival [31], including two who bear the longest continuously functioning allografts in the world today (more than 35.5 years) and have been free from immunosuppression for 32 and 4 years, respectively [109].

The practical and theoretic implications of these observations were recognized throughout the report [31]:

A state of relative immunologic non-reactivity seems to have been produced which has lasted for as long as 6 months. ... It is not known whether this is due to a change in the antigenic properties of the homograft, or to an alteration in the specific [host] response to the stimulus of the grafted tissues. The apparent host-graft adaptation does, however, provide some hope for prolonged functional survival... . It would seem probable that the [therapeutic] principles, as defined with the kidney, can eventually be applied to other organ homografts... . The prior knowledge that a rejection crisis is almost a certainty and that it usually can be managed by relatively conservative means should serve as a deterrent to the excessive use of measures that may cause fatal bone marrow depression... . It is also conceivable that the avoidance of a primary host-graft reaction by these means [excessive immunosuppression] would prevent the adaptive process.

At the time this bellwether series was compiled between the autumn of 1962 and April 1963, the only other active clinical transplantation programs in the United States were in Richmond (directed by David Hume) [110] and at the Peter Bent Brigham Hospital in Boston (directed by Joseph Murray and John Merrill) [111]. The important earlier program of Willard Goodwin at UCLA (see earlier [93]) had been closed because all of the recipients died in less than 5 months. In Europe, TBI briefly remained the preferred treatment at the long-standing Paris centers of Jean Hamburger and Rene Kuss, whereas Michael Woodruff of Edinburgh had begun testing azathioprine [112].

The results in the Colorado series, and more importantly an exact description of the strategy that had been used to induce variable degrees of incomplete tolerance (Table 4), created a surge of new activity. Within 12 months new kidney transplant centers proliferated in North America and Europe. Most of these second-generation programs remain in operation today.

The observations in the original kidney recipients were promptly confirmed. However, the proposed explanation for these successes (i.e., graft alteration plus loss of specific immunologic responsiveness [31]) was controversial and remained so for the next three decades (see Allograft Acceptance versus Acquired Tolerance, below). Except for reports from the University of Colorado, the term "tolerance" was studiously avoided from 1964 onward when referring to the long-surviving dogs and human kidney recipients produced by the end of 1963.

The article most often quoted as contravening tolerance was that of Murray et al. [106] despite the fact that, as the authors took pains to make clear, the evidence in their report was inconclusive and involved only two canine experiments of a potentially crucial nature. The two long-surviving dogs had been given renal homografts 9 and 18 months previously and had been treated for most of these times with one of the purine analogues. Renal function

was deteriorating at the time contralateral kidneys from the original donors were transplanted. The second organs were rejected after 23 and 3 days, respectively, as would be expected.

In commending Murray's 1964 report and conclusions, Medawar wrote [116]¹:

There is, however, something special about renal homografts, as [Michael] Woodruff's appraisal in this volume makes very clear. A synoptic survey of more than 1000 renal homografts in dogs carried out by Murray and his colleagues [Murray, Ross Shiel, Moseley, Knight, McGavic & Dammin, 1964] [106] has shown that foreign kidneys do sometimes become acceptable to their hosts for a reason other than acquired tolerance in the technical sense. ... There has been an adaptation of some kind—a possibility Woodruff has long urged us not to overlook [117, 118] though there is no reason to believe it an antigenic adaptation.

One possible explanation is the progressive and perhaps very extensive replacement of the vascular endothelium of the graft by endothelium of host origin, a process that might occur insidiously and imperceptibly during a homograft reaction weakened by immunosuppressive drugs.... Another possibility, raised by R.Y. Calne [though not mentioned by him in his contribution to this volume] is the laying down of a protective coat of host antibody on the endothelial inner surface of the graft—an explanation which would classify the phenomenon under the general heading of "enhancement."

These disclaimers notwithstanding, the commonality of the rejection barrier for different organs was self-evident, as was the likelihood that the means of inducing acceptance of one organ could be used for all the others [119]. There also was evidence from earlier experiments that a liver allograft could protect other donor tissues and organs. It had been noted in 1962 that intestine and pancreas had little histopathologic evidence of rejection in untreated canine recipients if they were components of multivisceral allografts that also included the liver [120]. These observations were confirmed 30 years later in a rat version of the same multivisceral procedures [121, 122].

Most convincingly at an experimental level, it was shown in 1964 that orthotopic canine liver allografts could induce and maintain their own acceptance far more frequently and permanently than renal allografts, even with a treatment course of azathioprine as short as 4 months [123, 124]. Soon thereafter, spontaneous engraftment was demonstrated after liver transplantation in untreated outbred pigs [125–129], many of which passed through self-resolving rejection crises [128, 130, 131].

Thus it already was clear by 1964–1965 that the liver is the most tolerogenic organ. During the late 1960s and early 1970s, Calne, Zimmerman, and Kamada formally proved that the liver tolerization extended to other donor tissues transplanted at the same time or later, first in untreated outbred pigs [132] and then without immunosuppression in selected rat strain combinations [133–135]. Although they were important, the experimental studies with hepatic allografts only affirmed the conclusion reached with the 1962–1963 experience in clinical renal transplantation suggesting that all organs were capable of inducing tolerance. As with liver allografts, the self-induction of donor-specific tolerance by heart and kidney allografts without the aid of immunosuppression was later demonstrated by Corry et al. [136] and Russell et al. [137] in selected mouse strain combinations.

¹Original numbers in the quote have been changed to those of current reference list. The quotation is otherwise verbatim.

The key mechanism of kidney-induced allograft acceptance was suggested as early as 1964 to be clonal exhaustion [138]. This concept was developed more fully for liver allografts in Figure 2, published in 1969 [139]. Induction of the activated clone by alloantigen was depicted via host macrophages rather than by antigen-presenting dendritic cells, which would not be described until 1973 [140]. In the text accompanying the figure, it was pointed out that exhaustion and deletion of an antigen-specific clone had been postulated by Schwartz and Dameschek as early as 1959 to be the mechanism of the tolerance to heterologous protein induced in rabbits with the aid of 6-MP [94]. In addition, Simonsen had suggested in 1960 that clonal exhaustion induced by allogeneic splenocytes could lead to the acquisition of tolerance in adult animals in the absence of immunosuppression [141].

The error of making a semantic distinction between tolerance and graft acceptance was understandable. The picture that had emerged from the remarkable accomplishments with clinical kidney transplantation between January 1959 and the spring of 1963 was not a product of new insight in immunology. Instead, successful organ transplantation was an intellectually troubling and inexplicable violation of the immunologic rules of the time. The revolution in immunology that had already begun and would continue for the next third of a century did little to change this view.

The Burnet antibody hypothesis of clonal selection (see earlier [14]) was validated and extended to cellular immunity by the late 1950s [142–144], but it had minimal influence on the clinical development of transplantation. Neither did many other key advances in immunology which were either contemporaneous with, or came after, the rise of organ transplantation. The role of the thymus in the ontology of the immune system and in the postnatal immune function of rodents was discovered in 1961 (by Jacques Miller [145, 146]). However, thymectomy in humans did not significantly alter either the early or late course of kidney transplant recipients [147, 148]. Lymphocytes were not formally assigned a function until 1963 (by James Gowans [149, 150]), although workers in transplantation were aware several years earlier that these mononuclear leukocytes were the cellular agents of allograft rejection [13, 151, 152] (Fig. 3). By the time the distinction was clearly established between T and B lymphocytes, transplantation was an established specialty of clinical medicine.

Thus the ascension of organ transplantation came as a surprise to most immunologists. Even as the clinical advances had begun to unfold, Burnet [144] had written in the *New England Journal of Medicine* that “much thought has been given to ways by which tissues or organs not genetically and antigenically identical with the patient might be made to survive and function in the alien environment. On the whole, the present outlook is highly unfavorable to success.” Pessimism also was deeply ingrained in conventional practitioners of medicine. Well into the 1960s editorials were published in major clinical journals questioning both the inherent feasibility and the ethical basis of transplantation procedures [153]. As a consequence, transplantation acquired a renegade image, a burden soon compounded by difficulties in extending its reach to the replacement of vital organs other than the kidney.

One dilemma, as it was perceived at the time, is shown in Figure 4 [154]. It was feared that chronic drug immunosuppression powerful enough to prevent organ allograft rejection would render the recipient hopelessly vulnerable to indigenous and environmental pathogens. Early reports of infectious disease complications in the early Colorado recipients [155] and elsewhere gave warning that dire consequences might, in time, be in store for all recipients. It also was suspected that immune surveillance to tumors would be eroded, a possibility that was verified but shown to be manageable by 1968 [156–158].

Autopsy studies in failed clinical cases revealed a typical pattern. Infections for which specific antibiotics were available could be largely controlled. However, opportunistic microorganisms of normally low pathogenicity were overrepresented and appeared at autopsy to be the main cause of death [159]. Of these infections, cytomegalovirus (CMV) was the most common and most lethal. The presence of *Pneumocystis carinii* as a co-infection with CMV [160] premonitored the lethal role of this combination of infectious agents in the AIDS epidemic in the nontransplant population that lay two decades ahead.

Maturation of Transplantation

Although it was entirely empiric, the practical framework required for the maturation of clinical transplantation was essentially complete by the end of 1963. Without knowing either the nature of the normal immune response or the way in which it had been subverted, it had been learned how to redirect the immune response reliably with the aid of immunosuppression. Surgical (see above) and preservation techniques (see later) had been developed for transplantation of all of the organs and are used currently with only minor modifications. Yet the field of organ transplantation stalled and now entered a phase that was euphemistically termed “consolidation.” The reason was the failure to find improved means to exploit the principles for controlling rejection that had been established with azathioprine and prednisone (Table 4).

Improved Immunosuppression

Antilymphoid Strategies—Between 1963 and 1979 the only significant advance in clinical immunosuppression was the introduction in 1966 of heterologous antilymphocyte globulin (ALG) [115, 162]. This was a logical extension of Gowan’s demonstration of the immunosuppressive effects of lymphoid depletion with thoracic duct drainage (TDD) in rats [149, 150]. In fact, Woodruff and Anderson showed that TDD and antilymphocyte serum (ALS) had additive effects [163].

Clinically used by Franksson and Blomstrand in 1963 to treat kidney recipients in Stockholm [164], TDD is an approach that resurfaced periodically during the next two decades (summarized in [165]). Conditioning with TDD prior to transplantation clearly reduced the frequency and vigor of kidney rejection, but 30 days of pretreatment was required in humans [165, 166] compared to the 5 days in Gowan’s rats [149, 150]. However, the inconvenience, complexity, and expense of TDD precluded widespread use [166]. For the same reasons, total lymphoid irradiation (TLI) [167], which also was an effective means of lymphoid depletion but with the disadvantage of not being quickly reversible, did not have a lasting impact on clinical transplantation [168, 169].

In contrast, ALG was a major development for two reasons. First, it was a critical factor in the emergence of extrarenal organ transplantation. Second, it was a prototype drug from which numerous variations evolved. The concept of mitigating cellular immunity with heterologous antibodies had been proposed by Ilya Metchnikoff at the end of the nineteenth century [170] and was revitalized by Inderbitzen [171] and Waksman et al. [172] before Woodruff and Anderson [163], Levey and Medawar [173], Monaco, Wood, and Russell [174, 175], and other surgeons recognized its potential role in clinical transplantation.

In most of the animal investigations up to 1963 the anti-lymphocyte antibodies were raised in rabbits; and raw ALS was administered to all recipients. In preparation for clinical trials, horse anti-dog ALS was prepared, and the active moiety was refined from the gamma globulin [162]. After the product was shown to inhibit or reverse rejection in the canine kidney and liver transplant models [115], comparable horse anti-human ALG was produced

from the serum of horses immunized with leukocytes separated from human lymphoid organs (lymph nodes, spleen, thymus) [162].

The first clinical trial of ALG began in 1966. Daily injections were given to kidney recipients for 1 to 4 weeks postoperatively as a short-term adjunct to continuous azathioprine and prednisone [115]. After encouraging results were obtained in the kidney trial, liver transplantation was resumed, with long survival of several patients. The successful liver replacements during the summer of 1967 [20] expanded the horizon of transplantation to the other vital extrarenal organs. Within the succeeding 27 months, heart [21, 22], lung [23], and pancreas [24] transplantation was accomplished, using variations of the treatment shown in Table 4. As had happened with kidney centers in 1963, a wild proliferation of extrarenal (particularly heart) programs followed. However, almost all of them closed within the next 2 years because of an overwhelming failure rate.

Polyclonal ALG was never used in more than about 15% of kidney transplant cases reported to registries up to the early 1980s, in part because it was in no sense a standardized drug such as azathioprine or prednisone. Although the use by Najarian and Simmons [176] of known numbers of cultured human lymphoblasts for accurately timed horse immunization improved the predictability of the ALG potency, batch-to-batch variations in potency remained problematic. “Antibody therapy” came of age with monoclonal antibodies, whose production was made feasible by the hybridoma technology of Kohler and Milstein [177]. OKT3, the first-generation monoclonal antibody, was directed at all T lymphocytes [178]. Subsequent antibody preparations, which include less immunogenic humanized “hybrids,” have been directed at discrete targets such as T cell subsets, adhesion molecules, and T cell or interleukin-2 receptors. However, when these agents are used, the “induction” strategy has been essentially the same as with the original crude ALG.

Cyclophosphamide—Although the experience during this middle era, defined by the first triple-drug regimen, demonstrated the feasibility of transplanting the vital extrarenal organs, it also indicated that further progress would require better baseline immunosuppression. Substitution of the alkylating agent cyclophosphamide for azathioprine was such an effort [113]. The characteristic cycle of immunologic confrontation and resolution leading to graft acceptance was no different with this drug than with azathioprine-based therapy. When the results with kidney and liver transplantation were almost identical to those using azathioprine but at a higher price of complications, the trials were discontinued [114]. Although cyclophosphamide therapy became a footnote in the history of organ transplantation, it continued to play a role in bone marrow transplantation.

Cyclosporine—Another decade would pass before the greater potency of cyclosporine would make transplantation of the liver and other cadaveric organs (including the kidney) a reliable service. Cyclosporine, an extract from the fungi *Cylindrocarpum lucidum* and *Trichoderma polysporum*, was discovered by Dreyfuss et al. [179] and characterized biochemically by Ruegger et al. [180] and Petcher et al. [181]. It was shown to be immunosuppressive by Borel et al. [182–184] with multiple test systems including skin allotransplantation in mice, rats, and guinea pigs.

The drug depressed humoral and cellular immunity and had a preferential and quickly reversible action against T lymphocytes. Unlike azathioprine and cyclophosphamide, these effects were not accompanied by bone marrow depression or other prohibitive organ toxicity. The ability of cyclosporine to prevent or delay rejection of the heart, kidney, liver, or pancreas was promptly shown in rats, rabbits, dogs, and pigs by Kostakis et al. [185], Calne [186–188], and Green and Allison [189] and their associates. There was no hint in

these preclinical studies that nephrotoxicity would be the dose-limiting factor in human trials.

The toxicity profile of cyclosporine became evident in Calne's initial evaluation of cyclosporine in human recipients of 32 kidneys, 2 pancreases, and 2 livers reported during 1978–1979 [190, 191]. The ability of the drug to prevent rejection, alone or in combination with myelotoxic drugs, exceeded anything previously seen. However, the requisite overdosage caused multiple serious side effects: nephrotoxicity, neurotoxicity, diabetogenicity, a 10% incidence of B cell lymphoma, and cosmetic changes (gingival hyperplasia, facial brutalization, and hirsutism).

When cyclosporine in lower doses was combined with prednisone in the treatment algorithm shown in Table 4, the prognosis of cadaver kidney recipients was improved [192], and transplantation of the liver [193], heart [194, 195], and lungs [196] was brought to the level of a practical clinical service. Recapitulating the aborted avalanche of 1967, many new extrarenal programs appeared, joining the five extant liver centers [Denver (from 1963), Cambridge (1968), Hannover (1972), Paris (1974), Groningen (1977)] and the single remaining heart program [Stanford (from 1968)]. This time, most of the programs flourished.

Tacrolimus—Cyclosporine was the unchallenged baseline immunosuppressant for all varieties of transplantation until it was shown in 1989 that intractably rejecting liver allografts could be regularly rescued by replacing cyclosporine with tacrolimus [197], an extract of *Streptomyces tsukubaensis* discovered by Kino and Goto et al. [198]. Tacrolimus was tested initially in a rat cardiac transplant model by Ochiai et al. [199] and soon thereafter by Murase et al. in rats [200, 201] and by Todo et al. in dogs [202, 203] and subhuman primates [203, 204].

In addition to numerous confirmatory reports of its ability to rescue about 75% of intractably rejecting human liver allografts [205], tacrolimus could salvage an equal proportion of rejecting hearts, kidneys, and other organs [206]. In virtually all such cases, a switch back to cyclosporine was never made. Consequently, clinical trials using tacrolimus primarily were begun [206–208].

By early 1990 more than 150 liver, kidney, heart, and heart-lung recipients had been treated from the time of transplantation with immunosuppression based on tacrolimus rather than cyclosporine [209]. It was learned from this experience that the three major side effects of the drug (nephrotoxicity, neurotoxicity, diabetogenicity) were comparable to those of cyclosporine. Hypertension and hyperlipidemia were less common than in historical cyclosporine controls. The cosmetic effects of cyclosporine were not seen (Table 5).

The effective use of both cyclosporine and tacrolimus required the same pattern recognition and therapeutic response that have guided organ transplantation since its inception (Table 4). The dose ceilings of the four widely used baseline immunosuppressants were imposed by toxicity: myelotoxicity for azathioprine and cyclophosphamide and the more complex side effects shown in Table 5 for cyclosporine and tacrolimus. The dose floors were revealed by the breakthrough of rejection. Because none of the four drugs could be used alone, they had to be incorporated into “cocktails” in which the requisite doses of the individual drug constituents were determined on a case-to-case basis by trial and error. Dose-maneuverable prednisone has remained a constant for 36 years, but steroid dependence declined with the more potent baseline agents.

The lead organ for azathioprine was the kidney. The developmental responsibility for cyclosporine was shared by the kidney and liver, and the liver bore the principal burden for tacrolimus [197, 205, 207, 209–213]. Progress with one kind of organ allograft inevitably meant progress for all. Thus survival of each kind of organ graft rose in the same three distinct leaps between 1962 and 1998 (Fig. 5). With tacrolimus, the intestine was no longer a “forbidden” organ [214–216].

Ripple Effect

Organ Procurement and Preservation

The sudden arrival of clinical kidney transplantation during 1962–1963 was so unexpected that little collateral research or other formal preparation had been made to preserve organs. Although kidneys were successfully transplanted in the pioneer identical twin cases despite protracted periods of warm ischemia, the maturation of clinical transplantation could not proceed without effective organ conservation. This was accomplished at first with total body hypothermia of living volunteer kidney donors [217] using methods developed by cardiac surgeons for open heart operations [218]. In the experimental laboratory, Lillehei et al. [40] simply immersed the excised intestine in iced saline before its autotransplantation, a method also used by Shumway when developing experimental and clinical heart and heart-lung transplantation [45–47]. Thus the principle of hypothermia was understood at an early time, although not efficiently applied.

The first major innovation in hypothermia was in the laboratory, when canine liver allografts were cooled by infusion of chilled fluids into the vascular bed of hepatic allografts via the portal vein [43]. Before this time, dogs after liver transplantation was almost never survived, whereas afterward success became routine. In a logical extension to clinical kidney transplantation, the practice was introduced in 1963 of infusing chilled lactated Ringer’s or low-molecular-weight dextran solutions into the renal artery of kidney grafts immediately after their removal [219].

Today, intravascular cooling is the first step in the preservation of all whole-organ grafts. For cadaver donors, this is most often done in situ by some variant of the technique described by Marchioro et al. [220] (Fig. 6). This method for the continuous hypothermic perfusion of cadaveric livers and kidneys was used clinically long before the acceptance of brain death. Ackerman and Snell [221] and Merkel, Jonasson, and Bergan [222] popularized the simpler core cooling of cadavers with cold electrolyte solutions infused into the distal aorta.

Organ Procurement—Until 1981 transplantation of the extrarenal organs was an unusual event. By late 1981, however, it had become obvious that liver and thoracic organ transplant procedures were going to be widely used. A method of multiple organ procurement was required by which the kidneys, liver, heart, and lungs or various combinations of these organs could be removed without jeopardizing any of the individual organs. “Flexible techniques” were developed [223, 224] that were quickly adopted worldwide. With these methods all organs to be transplanted are cooled in situ, rapidly removed in a bloodless field, and dissected on a back table. The sharing of organs from a common donor by recipient teams from widely separated centers became routine by the mid-1980s.

Ex Vivo Perfusion—Extension of the safe period after initial cooling has followed one of two prototype strategies, developed with kidneys or livers and applied secondarily to other organs. One approach that was extensively evaluated by Alexis Carrel and the aviator Charles A. Lindberg was to simulate normal physiologic conditions with ex vivo perfusion techniques [225]. This concept was modified by Ackerman and Barnard [226], who

provided the isolated organs with a continuous low-flow renal arterial circulation using a perfusate primed with blood and oxygenated within a hyperbaric oxygen chamber. This technique also permitted good preservation of hepatic allografts for as long as a day [227]. However, the complexity of the method precluded its general use.

Elimination of the hemoglobin and hyperbaric chamber components by Belzer et al. [228] resulted in satisfactory kidney preservation for up to 2 to 3 days. The asanguineous perfusion technique eventually was abandoned in most kidney transplant centers when it was learned that the quality of 2-day preservation was no better than with the simpler “slush” methods (see below). Nevertheless, it is expected that refinement of perfusion technology will someday permit true organ banking.

“Slush” Preservation—With the so-called static methods, fluids of differing osmotic, oncotic, and electrolyte composition are infused into the allograft before placing it in a refrigerated container [229, 230]. The solution described by Collins, Bravo-Shugarman, and Terasaki [229] (which resembles intracellular electrolyte concentrations) or modifications of it were used for almost two decades. Renal allograft preservation was feasible for 1 to 2 days, long enough to allow tissue matching and sharing of organs over a wide geographic area. Experiments with hepatic allografts by Benichou et al. [231] using the Collins–Terasaki solution and by Wall et al. [232] with the plasma-like Schalm solution led directly to liver sharing among cities but with a time limitation of only 6 to 8 hours.

Introduction of the University of Wisconsin (UW) solution to liver transplantation by Belzer, Jamieson, and Kalayoglu [233, 234] was the first major development in static preservation since the Collins–Terasaki solution [235]. The superiority of the UW solution for preservation of the kidney and other organs was promptly demonstrated in experimental models and confirmed in clinical trials [236–241]. The UW preservation doubled or tripled the time of safe preservation of the various allografts, making national and international sharing of most organs an economic and practical objective.

Life Sciences—While occupying its own unique niche, transplantation has drawn from and in turn enriched all of the other basic and clinical scientific disciplines. Aside from changing the philosophy by which organ-defined specialties of surgery and medicine are practices, transplantation grew parallel with and contributed in a major way to advances in immunology, pharmacology, oncology (e.g., the role of tumor immune surveillance [158, 242]), infectious disease, intensive care, and anesthesiology. Study of each of the allografts has yielded an organ-specific harvest of special information. Examples include a better understanding of diabetes mellitus with pancreas transplantation and the effects of denervation on cardiopulmonary function with heart and lung transplantation.

The liver became the key organ in unmasking the secrets of acquired tolerance because of its large content of immunocompetent leukocytes (see earlier and Allograft Acceptance versus Acquired Tolerance, below). In addition, the functional complexity of the liver and its metabolic interactions with other abdominal viscera have made hepatic transplantation a “mother lode” for physiologic studies [243].

During the course of determining the optimal revascularization of auxiliary livers transplanted to ectopic sites or to the normal location [43, 244, 245], it was found that endogenous insulin is a liver growth factor [246, 247], the first such hepatotrophic factor to be identified. Using transplantation-derived models, a family of other molecules was delineated with insulin-like hepatotrophic properties [248]. Eventually the gene was discovered that expresses one of them (augmenter of liver regeneration) [249–251]. The

hepatotrophic factors, most of which are cytokines [e.g., hepatocyte growth factors (HGF)], regulate liver size, structure, regeneration, and metabolic homeostasis.

Studies of hepatotrophic physiology led directly or indirectly to liver replacement for cure of more than two dozen hepatic-based inborn errors of metabolism [252], including familial hypercholesterolemia [73, 74]. The role of hepatic transplantation in first suggesting, and then proving, that the liver governs cholesterol metabolism has been described elsewhere [73, 74, 252, 253]. Elucidation of the cellular and molecular mechanisms was rewarded by bestowal of the 1985 Nobel Prize to Brown and Goldstein (Table 2).

Immunologic Screening

The importance of the genetically determined major histocompatibility complex (MHC) in determining the immune response to allografts was evident from investigations by George Snell in inbred mice [254], which in turn derived from the work of Peter Gorer [255]. However, the information was not clinically applicable. Thus immunologic screening of donors and recipients was not done during the volatile developmental period of 1959–1963 [1]. The possibility of tissue matching did not begin to emerge until the discovery by Dausset of the first human leukocyte antigen (HLA) in 1958 [256] and the discovery that same year by Van Rood et al. [257] of anti-leukocyte antibodies (soon shown to be HLA-directed) in the sera of pregnant women. The report in 1964 by Terasaki and McClelland [258] of the microcytotoxicity test, with which HLA antigens could be detected serologically in minute quantities of sera, was a critical development in moving forward with the classification of the antigens.

Crossmatch Principle

As it turned out, the greatest impact of pretransplant tissue matching has been the prevention of hyperacute rejection by observing ABO compatibility guidelines and routine use of the cytotoxicity crossmatch.

ABO Compatibility—Hyperacute rejection was first observed more than 30 years ago when ABO-mismatched renal allografts were transplanted into patients who had preformed anti-graft ABO isoagglutinins [54, 259]. After kidneys were lost on the operating table, arteriograms of the infarcted organs showed nonfilling of the small vessels, correlating histopathologically with widespread thrombotic occlusion of the microvasculature. It was concluded that high-affinity isoagglutinins in the recipient serum had bound to A or B antigens in the graft vessels and parenchymal cells. This was consistent with the rapid changes in recipient isoagglutinin titers that followed organ revascularization. The guidelines formulated from this experience [54, 259] were designed to avoid such antibody confrontations (Table 1).

The ABO rules also apply to heart, liver, and other organ transplantation. As was originally observed in 1963 with ABO-mismatched kidneys, however, [54, 259], not all organs placed in the hostile environment of anti-graft isoagglutinins meet the same fate. In fact, the longest continuously functioning renal allograft in the world [109] is a B⁺ kidney donated to a then 38-year-old A⁺ male recipient by his younger sister on January 31, 1963. In addition, it was learned at an early time that the liver is more resistant to antibody attack than other organs [260].

In histocompatibility studies in which human volunteers were sensitized with purified A and B blood group antigens, causing variably increased titers of isoagglutinins, Rapaport et al. [261] showed accelerated or hyperacute (white graft) rejection of ABO-incompatible skin

grafts transplanted to recipients with high titers. This completed the circle of evidence indicting anti-graft antibodies as the precipitating cause of hyperacute organ rejection.

With Non-ABO Antibodies—In 1965 hyperacute rejection of a kidney by an ABO-compatible recipient was reported for the first time by Terasaki et al. [262]. Terasaki's observation that the serum of the recipient of a live donor kidney contained preformed anti-graft lymphocytotoxic antibodies was promptly confirmed in similar cases by Kissmeyer-Nielsen et al. [263] and others [264, 265]. Evidence of a cause-and-effect relation in the single first case was so clear that Terasaki recommended and immediately introduced his now universally applied lymphocytotoxic crossmatch test [262, 266].

It has been shown in presensitized animals and humans that antibodies, clotting factors, and formed blood elements were rapidly cleared by the hyperacutely rejecting grafts [267, 268]. Local fibrinolysis from the renal vein also was a consistent finding; and in exceptional cases there were systemic coagulopathies with disseminated intravascular coagulation (DIC) [269, 270]. The findings are comparable to those seen with the Arthus reaction, inverse anaphylaxis, generalized Shwartzman reaction, and other models of innate immunity [265, 269, 270].

Non-HLA antibodies such as anti-vascular endothelial cell antibodies also have been associated with hyperacute or accelerated rejection [271, 272]. The vulnerability of extrarenal organs to this kind of rejection was ultimately demonstrated experimentally [273–275] and clinically. Although the liver was the most antibody resistant [260], it too was placed at increased risk by the presensitized state [276]. Hyperacute rejection also has been documented in a small number of human organ recipients in the absence of detectable antibodies [265, 277].

Tissue Matching

Historically, it was predicted that tissue matching would have to be perfected if long-term engraftment of tissues and organs was to succeed with any degree of reliability and predictability. The prophecy was immediately fulfilled with bone marrow transplantation, in which anything less than a perfect or near-perfect match between the donor and recipient resulted in GVHD or rejection of the graft [27–30]. When similar expectations were not met in studies by Terasaki in kidney transplant recipients, the results initially were treated as a scientific scandal [278, 279]. When he later was proved to have been correct, Terasaki emerged as the father of HLA matching and as an enduring symbol of integrity.

Terasaki's investigations began with a retrospective study of the influence of HLA matching on the quality of outcome of patients with long-surviving kidney allografts [280], followed by a prospective trial in live donor kidney recipients treated with azathioprine and prednisone, with or without adjunct ALG [281]. Consistent with the results in the classic skin graft investigations in nonimmunosuppressed healthy volunteers by Rapaport and Dausset [282–284], HLA-matched allografts had the best survival and function, the least dependence on maintenance prednisone, and the fewest histopathologic abnormalities in routine 2-year postoperative biopsy specimens [285]. Unexpectedly, however, no cumulative adverse effect of mismatching in the kidney recipients could be identified.

The equally imprecise prognostic discrimination of HLA matching in cadaver kidney transplant cases also was first recognized by Terasaki (with Mickey et al. [286]) and has been evident in analyses up to the present time. With the large sample sizes in United Network for Organ Sharing (UNOS) and European databases, virtually every comparison of the different levels of mismatching showed statistical significance. However, the absence of a large or consistent matching effect unless there is a perfect or near-perfect match has

always been the same. In a recent study of more than 30,000 UNOS patients for whom optimal matches had been sought prospectively, approximately 85% of the cases were in the two- to five-HLA mismatch spectrum, where 1-year survival was clustered within 3%. Subsequent half-life projections thereafter were in the narrow spread of 9 to 11 years [287].

Terasaki's conclusions nearly three decades ago breathed life into the still struggling field of liver, heart, and lung transplantation. It was a relief to know that the selection of donors with random tissue matching would not result in an intolerable penalty. A quarter of a century passed before it could be explained why HLA matching was critical for bone marrow, but not organ, transplantation (see the section that follows).

Allograft Acceptance versus Acquired Tolerance

During the Festschrift at Harvard honoring Paul Russell's retirement in late November 1990, Norman Shumway told me and Leslie Brent about his textbook on thoracic transplantation for which he wanted two chapters: one explaining the classic immunologic tolerance exemplified by bone marrow transplantation and the other defining the presumably different mechanisms of whole organ allograft acceptance. On learning that I thought the two were the same in principle, Shumway assigned me the task of defending this opinion [288].

Evidence was obtained first from investigation of long-surviving human liver, kidney, and other organ recipients [32, 33, 289–291] and then from detailed confirmatory animal studies [292–295]. The observation that all 30 patients tested had low level (micro) chimerism conformed perfectly with the hypothesis being tested that allograft acceptance involved not only chimerism but a bidirectional immune reaction (Fig. 7). The relative strengths of the opposing immune reactions following organ transplantation were simply the reverse of those following bone marrow transplantation to the cytoablated recipient (summarized in [34, 109]). With this paradigm, it has been possible to view the historic milestones of clinical organ and bone marrow transplantation in a coherent way [35].

Historically, an organ allograft had been envisioned as defenseless and vulnerable to immunologic attack in proportion to its histoincompatibility (Fig. 8, top left). The same dogma in reverse (i.e., the host was the defenseless target) was the conventional view of bone marrow transplantation (Fig. 8, top right). Only two pioneer workers raised objections to the definition of transplantation immunology in terms of a unidirectional immune reaction. In 1960–1961, Simonsen [141] and then Michie, Woodruff, and Zeiss [296] postulated that the two populations of immune cells in neonatally tolerant mice managed to coexist in a stable state by becoming mutually nonreactive while retaining the ability to function collaboratively (i.e., in a joint immune response to infection).

Although this heretical suggestion resembled the concept summarized in Figures 7 to 11, the Simonsen–Woodruff hypothesis was recanted in 1962 [297], ostensibly because no experimental support could be found for it. More importantly, however, it had been advanced in a nonreceptive climate in which “group think” had already turned in a different direction. For the next 30 years transplantation immunity and tolerance were conceived as products of unidirectional immune reactions of the kind that could be studied *in vitro* by one-way mixed lymphocyte culture techniques described by Bain and Lowenstein [298] and Bach and Hirschhorn [299].

After chimerism was discovered in organ recipients in 1992–1993 [32–34] it was recognized that the interaction of the coexisting donor and recipient leukocyte populations was the common factor that underlay both the “acceptance” induced by whole organ allografts (Fig. 8, bottom left) and the tolerance induced with bone marrow (Fig. 8, bottom right). This context closed the 30-year intellectual gap between the fields of organ and bone marrow

transplantation. Organ-associated chimerism then could be identified in a continuum of classic tolerance models [5, 11, 167, 300–302] beginning with the original observations by Owen in freemartin cattle (Fig. 9).

Organ Engraftment

The immunocompetent donor leukocytes in organ transplantation are highly immunogenic, multilineage “passenger leukocytes” of bone marrow origin (including stem and dendritic cells) that migrate preferentially to host lymphoid organs and are replaced in the graft by host cells. The result is widespread antigen-specific immune activation of the coexisting donor and recipient cells, each by the other, which proceeds in successful cases to variable reciprocal clonal exhaustion and then deletion (Fig. 7).

Engraftment under clinical circumstances requires an umbrella of immunosuppression to prevent one cell population from destroying the other; but in some experimental models it occurs spontaneously (e.g., after pig liver transplantation and in many rodent models). The “nullification” of the two arms explains the poor prognostic value of HLA matching for organ versus bone marrow transplantation (Table 6) and the low incidence of GVHD following the engraftment in noncytoablated recipients of immunologically active organs, such as the intestine and liver.

In addition to inducing clonal activation and exhaustion by trafficking to host lymphoid organs, donor leukocytes that survive the initial destructive immune reaction migrate secondarily to nonlymphoid areas, where they do not generate an immune response (“immune indifference”). From here they may “leak” periodically to the host lymphoid organs and maintain clonal exhaustion. With clonal exhaustion/deletion and immune indifference in combination, both of which are regulated by the migration and localization of the antigen [34], the four interrelated events shown in Figure 10 must occur close together to have organ engraftment: double acute clonal exhaustion, maintenance clonal exhaustion (which frequently waxes and wanes), and loss of graft immunogenicity as the organ is depleted of its passenger leukocytes.

Bone Marrow Tolerance

Pretransplant cytoablation renders the recipient susceptible to immune attack by donor immune cells (i.e., GVHD), control of which frequently becomes the principal objective of immunosuppression, rather than the prevention of rejection (Table 6). Because complete destruction of host leukocytes is not possible with conventional doses of cytoablation [303], the remaining cells stimulate an alloresponse by mature or maturing donor T cells. Nevertheless, under immunosuppressive treatment, a weak host-versus-graft reaction mounted by these few recipient cells and a parallel graft-versus-host reaction mounted by the donor bone marrow cells may eventually result in reciprocal tolerance by deletion. These processes represent a mirror image of the events after organ transplantation (Fig. 8, bottom right).

Relation to Infectious Disease

Noncytopathic Microorganisms—Early workers in transplantation [304, 305] recognized the resemblance of allograft rejection to the response against infections associated with delayed hypersensitivity, exemplified by tuberculosis. With the demonstration of the MHC-restricted mechanisms of adaptive infectious immunity by Doherty and Zinkernagel in 1973 [306–309], it became obvious that allograft rejection must be the physiologic equivalent of the response to this kind of infection. Microorganisms that generate such an adaptive immune response are generally intracellular and have no or low cytopathic qualities [310].

Although MHC-restricted host cytolytic T lymphocytes recognize only infected cells, elimination of all the infected cells could disable or even kill the host. Consequently, mechanisms have evolved that can temper or terminate the immune response, allowing both host and pathogen to survive [310, 311]. They are the same two mechanisms that allow survival of allografts (i.e., clonal exhaustion/deletion and immune indifference) [34], both of which are governed by antigen migration and localization [34, 310, 311]. However, unlike the complex dual immune response of transplantation, infectious immunity is essentially a host-versus-pathogen reaction.

The analogies between transplantation and an infection with disseminated noncytopathic microorganisms can be exemplified by the common hepatitis viruses, as shown in Figure 11 [34, 310, 311]. The pathogen (antigen) load may rapidly increase during the so-called latent period but then be dramatically and efficiently controlled by antigen-specific effector T cells, which then subside (Fig. 11, far left panel). The transplantation analogues are acute irreversible rejection (or intractable GVHD). Alternatively, a continuously high antigen load with an antigen-specific immunologic collapse (Fig. 11, second panel) is equivalent to unqualified acceptance of an allograft.

Between these two extremes, the persistence of both the infectious agent and a strong immune response results in serious immunopathology (e.g., chronic active hepatitis with HBV or HCV infection) comparable to chronic rejection after liver transplantation (Fig. 11, third panel) or uncommonly GVHD. The conditions in the cytoablated bone marrow recipient mimic those of an infection by microorganisms (e.g., rabies and wart viruses) that avoid immune activation by not migrating through (or to) host lymphoid organs (Fig. 11, right panel) [34].

Because immunity and tolerance to alloantigens follow the same rules as the response to noncytopathic microorganisms [34], it is not possible with current transplantation practices to induce tolerance to allografts on one hand without risking unwanted tolerance to pathogens on the other. In this context, the historical anxiety depicted in Figure 4 was correct.

Cytopathic Microorganisms—There is no MHC-restricted safety valve for cytopathic microorganisms that are typically extracellular and generate the full resources of the innate and the adaptive immune system [310, 311]. An uncontrollable innate immune response involving the effectors shown in Table 7 is provoked by discordant xenografts expressing the Gal α Gal epitope, an epitope that also is found on numerous cytopathic bacteria, protozoa, and viruses.

The clinical use of such discordant animal donors requires changing the xenogeneic epitope to one that mimics a noncytopathic profile or else eliminating the epitope [312]. Although chimpanzees and baboons do not express the Gal antigen, the clinical xenografts transplanted from these subhuman primate donors in 1963 [51, 52] ultimately were damaged by an uncontrollable innate immune reaction, dominated by complement activation. Similar innate immune mechanisms were recognized during the 1960s to be responsible for the hyperacute destruction of ABO-incompatible allografts or allografts transplanted to presensitized recipients (see earlier) [265–270].

Self/Non-self Discrimination

Survival in a hostile environment requires the ability to mount a protective immune response while avoiding a reaction of the immune system against self. Transplantation has succeeded because it has not lethally eroded this capability, which depends ultimately on the governance of immunologic responsiveness or unresponsiveness by migration and

localization of antigen [34]. Because the fetus possesses early T cell immune function [313–315] the ontogeny of self/non-self discrimination during fetal development can be explained by the same mechanisms as acquired tolerance during later life. Autoimmune diseases then reflect unacceptable postnatal perturbations of the prenatally established localization of self antigens in nonlymphoid versus lymphoid compartments [34].

Conclusions

The lesson described in this chapter has been learned many times before: All knowledge can be traced to its roots and ultimately to a seed. For clinical transplantation, the historical beginning was Medawar's recognition that rejection is an immune reaction. Only two primary roots sprang from this seed. One was the demonstration by Billingham, Brent, and Medawar in 1953 that tolerance could be acquired by producing stem cell-driven hematolymphopoietic chimerism [5]; this concept ultimately led to bone marrow transplantation in humans. The other root was the demonstration during 1962–1963 that kidney allografts could consistently self-induce tolerance with the aid of immunosuppression [31]; all further developments in organ transplantation derived from this discovery. The assumption reached by consensus during the early 1960s that the two roots reflected different immune mechanisms led to inadequate explanations of organ allograft acceptance and clouded the meaning of successful bone marrow transplantation.

The false assumption, which promptly became dogma, saddled succeeding generations of scientists and clinicians with a context that precluded synthesis of a clarifying central principle of immunology that could be applied to all transplant, much less nontransplant, circumstances. After it was discovered in 1992 that organ recipients had persistent microchimerism, it was possible to see the essential commonality of organ and bone marrow transplantation, to relate observations after these procedures to the immune response to infectious diseases and neoplasms, and to explain the genesis of self/non-self discrimination.

Acknowledgments

This study was supported in part by research grants from the Veterans Administration and Project Grant DK-29961 from the National Institutes of Health, Bethesda, MD.

References

1. Terasaki, P., editor. History of HLA. Ten Recollections. Los Angeles: UCLA Tissue Typing Laboratory; 1990. p. 1-269.
2. Terasaki, PI., editor. History of Transplantation. Thirty-Five Recollections. Los Angeles: UCLA Tissue Typing Laboratory; 1990. p. 1-704.
3. Gibson T, Medawar PB. The fate of skin homografts in man. *J Anat.* 1943; 77:299. [PubMed: 17104936]
4. Medawar PB. The behavior and fate of skin autografts and skin homografts in rabbits. *J Anat.* 1944; 78:176. [PubMed: 17104960]
5. Billingham RE, Brent L, Medawar PB. "Actively acquired tolerance" of foreign cells. *Nature.* 1953; 172:603. [PubMed: 13099277]
6. Traub E. Persistence of lymphocytic choriomeningitis virus in immune animals and its relation to immunity. *J Exp Med.* 1936; 63:847. [PubMed: 19870509]
7. Murphy JB. Transplantability of malignant tumors to the embryos of a foreign species. *JAMA.* 1912; 59:874.
8. Murphy JB. Factors of resistance to heteroplastic tissue-graftings. III Studies in tissue specificity. *J Exp Med.* 1914; 19:513. [PubMed: 19867789]
9. Billingham R, Brent L, Medawar P. Quantitative studies on tissue transplantation immunity. III Actively acquired tolerance. *Philos Trans R Soc Lond (Biol).* 1956; 239:357.

10. Hasek M. Vegetavni hybridisace zivocichu spojenim krevnich obehu v embryonalnim vyvoji. *Cesk Biol.* 1953; 2:265.
11. Owen RD. Immunogenetic consequences of vascular anastomoses between bovine twins. *Science.* 1945; 102:400. [PubMed: 17755278]
12. Anderson D, Billingham RE, Lampkin GH, Medawar PB. The use of skin grafting to distinguish between monozygotic and dizygotic twins in cattle. *Heredity.* 1951; 5:379.
13. Starzl TE, Butz GW Jr. Surgical physiology of the transplantation of tissues and organs. *Surg Clin North Am.* 1962; 42:55. [PubMed: 13916394]
14. Burnet, FM.; Fenner, F. *The Production of Antibodies.* 2. Melbourne: Macmillan; 1949. p. 1-142.
15. Billingham R, Brent L. A simple method for inducing tolerance of skin homografts in mice. *Trans Bull.* 1957; 4:67.
16. Billingham R, Brent L. Quantitative studies on transplantation immunity. IV Induction of tolerance in newborn mice and studies on the phenomenon of runt disease. *Philos Trans R Soc Lond (Biol).* 1959; 242:439.
17. Simonsen M. The impact on the developing embryo and newborn animal of adult homologous cells. *Acta Pathol Microbiol Scand.* 1957; 40:480. [PubMed: 13457893]
18. Brent, L. *A History of Transplantation Immunology.* San Diego: Academic; 1997. p. 1-482.
19. Merrill JP, Murray JE, Harrison JH, Friedman EA, Dealy JB Jr, Dammin GJ. Successful homotransplantation of the kidney between non-identical twins. *N Engl J Med.* 1960; 262:1251.
20. Starzl TE, Groth CG, Brettschneider L, Penn I, Fulginiti VA, Moon JB, Blanchard H, Martin AJ Jr, Porter KA. Orthotopic homotransplantation of the human liver. *Ann Surg.* 1968; 168:392. [PubMed: 4877589]
21. Barnard CN. What we have learned about heart transplants. *J Thorac Cardiovasc Surg.* 1968; 56:457. [PubMed: 4879092]
22. Dong, E.; Shumway, NE.; Lower, RR. *History of Transplantation: Thirty-Five Recollections.* Terasaki, PI., editor. Los Angeles: UCLA Tissue Typing Laboratory; 1991. p. 435-449.
23. Derom F, Barbier F, Ringoir S, Versieck J, Rolly G, Berzseny G, Vermeire P, Vrints L. Ten-month survival after lung homo-transplantation in man. *J Thorac Cardiovasc Surg.* 1971; 61:835. [PubMed: 4932557]
24. Lillehei RC, Simmons RL, Najarian JS, Weil R, Uchida H, Ruiz JO, Kjellstrand CM, Goetz FC. Pancreaticoduodenal allotransplantation: experimental and clinical observations. *Ann Surg.* 1970; 172:405. [PubMed: 4918002]
25. Goulet O, Revillon Y, Brousse N, Jan D, Canion D, Rambaux C, Cerf-Bensussan N, Buisson C, Hubert P, DePottier S, Mougenot JF, Fischer A, Ricour C. Successful small bowel transplantation in an infant. *Transplantation.* 1992; 53:940. [PubMed: 1533072]
26. Starzl TE, Rowe M, Todo S, Jaffe R, Tzakis A, Hoffman A, Esquivel C, Porter K, Venkataramanan R, Makowka L, Duquesnoy R. Transplantation of multiple abdominal viscera. *JAMA.* 1989; 261:1449. [PubMed: 2918640]
27. Mathe G, Amiel JL, Schwarzenberg L, Cattan A, Schneider M. Haematopoietic chimera in man after allogenic (homologous) bone-marrow transplantation. *BMJ.* 1963; 2:1633. [PubMed: 14066188]
28. Bach FH. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. *Lancet.* 1968; 2:1364. [PubMed: 4177931]
29. Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. *Lancet.* 1968; 2:1366. [PubMed: 4177932]
30. Thomas, ED. Allogeneic marrow grafting: a story of man and dog. In: Terasaki, PI., editor. *History of Transplantation: Thirty-Five Recollections.* Los Angeles: UCLA Tissue Typing Laboratory; 1991. p. 379-393.
31. Starzl TE, Marchioro TL, Waddell WR. The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. *Surg Gynecol Obstet.* 1963; 117:385. [PubMed: 14065716]
32. Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration, chimerism, and graft acceptance. *Lancet.* 1992; 339:1579. [PubMed: 1351558]

33. Starzl TE, Demetris AJ, Trucco M, Murase N, Ricordi C, Ildstad S, Ramos H, Todo S, Tzakis A, Fung JJ, Nalesnik M, Zeevi A, Rudert WA, Kocova M. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. *Hepatology*. 1993; 17:1127. [PubMed: 8514264]
34. Starzl TE, Zinkernagel RM. Antigen localization and migration in immunity and tolerance. *N Engl J Med*. 1998; 339:1905. [PubMed: 9862947]
35. Starzl TE, Demetris AJ. Transplantation milestones: viewed with one- and two-way paradigms of tolerance. *JAMA*. 1995; 273:876. [PubMed: 7869559]
36. Carrel A. The operative technique for vascular anastomoses and transplantation of viscera. *Lyon Med*. 1902; 98:859.
37. Woodruff, MFA. *The Transplantation of Tissues and Organs*. Springfield, IL: Charles C. Thomas; 1960. p. 1-777.
38. Simonsen M. Biological incompatibility in kidney transplantation in dogs. II Serological investigations. *Acta Pathol Microbiol Scand*. 1953; 32:36.
39. Dempster WJ. Kidney homotransplantation. *Br J Surg*. 1953; 40:447. [PubMed: 13042109]
40. Lillehei RC, Goott B, Miller FB. The physiologic response of the small bowel of the dog to ischemia including prolonged in vitro preservation of the bowel with successful replacement and survival. *Ann Surg*. 1959; 150:543. [PubMed: 14416956]
41. Moore FD, Smith LL, Burnap TK, Dallenbach FD, Dammin GJ, Gruber UF, Shoemaker WC, Steenburg RW, Ball MR, Belko JS. One-stage homotransplantation of the liver following total hepatectomy in dogs. *Transplant Bull*. 1959; 6:103. [PubMed: 13635834]
42. Moore FD, Wheeler HB, Demissianos HV, Smith LL, Balankura O, Abel K, Greenberg JB, Dammin GJ. Experimental whole organ transplantation of the liver and of the spleen. *Ann Surg*. 1960; 152:374. [PubMed: 13772284]
43. Starzl TE, Kaupp HA Jr, Brock DR, Lazarus RE, Johnson RV. Reconstructive problems in canine liver homotransplantation with special reference to the postoperative role of hepatic venous flow. *Surg Gynecol Obstet*. 1960; 111:733. [PubMed: 18979655]
44. Starzl TE, Kaupp HA Jr. Mass homotransplantation of abdominal organs in dogs. *Surg Forum*. 1960; 11:28.
45. Lower RR, Shumway NE. Studies on orthotopic homotransplantation of the canine heart. *Surg Forum*. 1960; 11:18. [PubMed: 13763847]
46. Lower RR, Stofer RC, Shumway NE. Homovital transplantation of the heart. *J Thorac Cardiovasc Surg*. 1961; 41:196. [PubMed: 13763849]
47. Lower RR, Stofer RC, Hurley EJ, Shumway NE. Complete homograft replacement of the heart and both lungs. *Surgery*. 1961; 50:842. [PubMed: 14466958]
48. Jaboulay M. Greffe du reins au pli du coude par soudures arterielles et veineuses [Kidney grafts in the antecubital fossa by arterial and venous anastomosis]. *Lyon Med*. 1906; 107:575.
49. Unger E. Nierentransplantation [Kidney transplantation]. *Wien Klin Wochenschr*. 1910; 47:573.
50. Groth CG. Landmarks in clinical renal transplantation. *Surg Gynecol Obstet*. 1972; 134:323.
51. Reemtsma K, McCracken BH, Schlegel JU, Pearl MA, Pearce CW, DeWitt CW, Smith PE, Hewitt RL, Flnner RL, Creech O Jr. Renal heterotransplantation in man. *Ann Surg*. 1964; 160:384. [PubMed: 14206847]
52. Starzl TE, Marchioro TL, Peters GN, Kirkpatrick CH, Wilson WEC, Porter KA, Rifkind D, Ogden DA, Hitchcock CR, Waddell WR. Renal heterotransplantation from baboon to man: experience with 6 cases. *Transplantation*. 1964; 2:752. [PubMed: 14224657]
53. Voronoy U. Sobre bloqueo del aparato reticuloendotelial del hombre en algunas formas de intoxicacion por el sublimado y sobre la transplantacion del rinon cadaverico como metodo de tratamiento de la anuria consecutiva a aquella intoxicacion [Blocking the reticuloendothelial system in man in some forms of mercuric chloride intoxication and the transplantation of the cadaver kidney as a method of treatment for the anuria resulting from the intoxication]. *Siglo Med*. 1937; 97:296.
54. Starzl, TE. *Experience in Renal Transplantation*. Philadelphia: Saunders; 1964. Patterns of permissible donor-recipient tissue transfer in relation to ABO blood groups; p. 37-47.

55. Ramsey G, Nusbacher J, Starzl TE, Lindsay GD. Isohemagglutinins of graft origin after ABO-unmatched liver transplantation. *N Engl J Med.* 1984; 311:1167. [PubMed: 6384786]
56. Hamilton DNH, Reid WA. Yu Yu Voronoy and the first human kidney allograft. *Surg Gynecol Obstet.* 1984; 159:289. [PubMed: 6382662]
57. Kuss R, Teinturier J, Milliez P. Quelques essais de greffe rein chez l'homme. *Mem Acad Chir.* 1951; 77:755. [PubMed: 14874917]
58. Dubost C, Oeconomos N, Nenna A, Milliez P. Resultats d'une tentative de greffe renale. *Bull Soc Med Hop Paris.* 1951; 67:1372.
59. Servelle M, Soulie P, Rougeulle J. Greffe d'une rein de supplicie a une malade avec rein unique congenital, atteinte de nephrite chronique hypertensive azatemique. *Bull Soc Med Hop Paris.* 1951; 67:99. [PubMed: 14821794]
60. Michon L, Hamburger J, Oeconomos N, Delinotte P, Richet G, Vaysse J, Antoine B. Une tentative de transplantation renale chez l'homme: aspects medicaux et biologiques. *Presse Med.* 1953; 61:1419. [PubMed: 13120746]
61. Merrill JP, Murray JE, Harrison JH, Guild WR. Successful homotransplantation of the human kidney between identical twins. *JAMA.* 1956; 160:277.
62. Hume DM, Merrill JP, Miller BF, Thorn GW. Experiences with renal homotransplantation in the human: report of nine cases. *J Clin Invest.* 1955; 34:327. [PubMed: 13233354]
63. Moore, FD. The Development of Tissue Transplantation. Philadelphia: Saunders; 1964. Give and Take; p. 1-182.
64. Billingham RE, Krohn PL, Medawar PB. Effect of cortisone on survival of skin homografts in rabbits. *BMJ.* 1951; 1:1157. [PubMed: 14830863]
65. Morgan JA. The influence of cortisone on the survival of homografts of skin in the rabbit. *Surgery.* 1951; 30:506. [PubMed: 14866694]
66. Cannon JA, Longmire WP. Studies of successful skin homografts in the chicken. *Ann Surg.* 1952; 135:60. [PubMed: 14895146]
67. Krohn PL. Effect of cortisone on second set skin homografts in rabbits. *Br J Exp Pathol.* 1954; 35:539. [PubMed: 13230410]
68. Lawler RH, West JW, McNulty PH, Clancy EJ, Murphy RP. Homotransplantation of the kidney in the human. *JAMA.* 1950; 144:844.
69. Murray G, Holden R. Transplantation of kidneys, experimentally and in human cases. *Am J Surg.* 1954; 87:508. [PubMed: 13138791]
70. Murray JE, Merrill JP, Harrison JH. Renal homotransplantation in identical twins. *Surg Forum.* 1955; 6:432. [PubMed: 13391513]
71. Brown JB. Homografting of skin: with report of success in identical twins. *Surgery.* 1937; 1:558.
72. Schlessinger, BS.; Schlessinger, JH., editors. The Who's Who of Nobel Prize Winners 1901-1990. 2. Phoenix, AZ: Oryx Press; 1991.
73. Starzl TE, Bilheimer DW, Bahnson HT, Shaw BW Jr, Hardesty RL, Griffith BP, Iwatsuki S, Zitelli BJ, Gartner JC Jr, Malatack JJ, Urbach AH. Heart-liver transplantation in a patient with familial hypercholesterolemia. *Lancet.* 1984; 1:1382. [PubMed: 6145836]
74. Bilheimer DW, Goldstein JL, Grundy SC, Starzl TE, Brown MS. Liver transplantation provides low-density-lipoprotein receptors and lowers plasma cholesterol in a child with homozygous familial hypercholesterolemia. *N Engl J Med.* 1984; 311:1658. [PubMed: 6390206]
75. Nossal GJV. Antibody production by single cells. *Nature.* 1958; 181:1419. [PubMed: 13552693]
76. Dempster WJ, Lennox B, Boag JW. Prolongation of survival of skin homotransplants in the rabbit by irradiation of the host. *Br J Exp Pathol.* 1950; 31:670. [PubMed: 14791918]
77. Cannon JA, Terasaki P, Longmire WP. Studies of factors influencing induced tolerance to skin homografts in the chicken. *Ann Surg.* 1957; 146:278. [PubMed: 13459278]
78. Main JM, Prehn RT. Successful skin homografts after the administration of high dosage x radiation and homologous bone marrow. *J Natl Cancer Inst.* 1955; 15:1023. [PubMed: 13233946]
79. Trentin JJ. Mortality and skin transplantability in x-irradiated mice receiving isologous or heterologous bone marrow. *Proc Soc Exp Biol Med.* 1956; 92:688. [PubMed: 13370496]

80. Mannick JA, Lochte HL, Ashley CA, Thomas ED, Ferrebee JW. A functioning kidney homotransplant in the dog. *Surgery*. 1959; 46:821. [PubMed: 14420698]
81. Storb R, Epstein RB, Bryant J, Ragde H, Thomas ED. Marrow grafts by combined marrow and leukocyte infusions in unrelated dogs selected by histocompatibility typing. *Transplantation*. 1968; 6:587. [PubMed: 4876499]
82. Epstein RB, Storb R, Ragde H, Thomas ED. Cytotoxic typing antisera for marrow grafting in litter mate dogs. *Transplantation*. 1968; 6:45. [PubMed: 4866738]
83. Hume DM, Jackson BT, Zukoski CF, Lee HM, Kauffman HM, Egdahl RH. The homotransplantation of kidneys and of fetal liver and spleen after total body irradiation. *Ann Surg*. 1960; 152:354. [PubMed: 13716793]
84. Rapaport FT, Bachvaroff RJ, Mollen N, Hirasawa H, Asano T, Ferrebee JW. Induction of unresponsiveness to major transplantable organs in adult mammals. *Ann Surg*. 1979; 190:461. [PubMed: 384942]
85. Van Bekkum, DW. Bone marrow transplantation: a story of stem cells. In: Terasaki, PI., editor. *History of Transplantation: Thirty-Five Recollections*. Los Angeles: UCLA Tissue Typing Laboratory; 1991. p. 395-434.
86. Murray JE, Merrill JP, Dammin GJ, Dealy JB Jr, Walter CW, Brooke MS, Wilson RE. Study of transplantation immunity after total body irradiation: clinical and experimental investigation. *Surgery*. 1960; 48:272. [PubMed: 14425430]
87. Murray JE, Merrill JP, Dammin GJ, Dealy JB Jr, Alexandre GW, Harrison JH. Kidney transplantation in modified recipients. *Ann Surg*. 1962; 156:337. [PubMed: 14477464]
88. Hamburger J, Vaysse J, Crosnier J, Tubiana M, Lalanne CM, Antoine B, Auvert J, Soulier JP, Dormont J, Salmon C, Maisonnnet M, Amiel JL. Transplantation of a kidney between non-monozygotic twins after irradiation of the receiver: good function at the fourth month. *Presse Med*. 1959; 67:1771.
89. Hamburger J, Vaysse J, Crosnier J, Auvert J, Lalanne CL, Hopper J Jr. Renal homotransplantation in man after radiation of the recipient. *Am J Med*. 1962; 32:854. [PubMed: 13904073]
90. Kuss R, Legrain M, Mathe G, Nedey R, Camey M. Homologous human kidney transplantation: experience with six patients. *Postgrad Med J*. 1962; 38:528. [PubMed: 14460913]
91. Kuss, R. Human renal transplantation memories, 1951 to 1981. In: Terasaki, PI., editor. *History of Transplantation: Thirty-Five Recollections*. Los Angeles: UCLA Tissue Typing Laboratory; 1991. p. 37-59.
92. Murray, JE. Nobel Prize lecture: the first successful organ transplants in man. In: Terasaki, PI., editor. *History of Transplantation: Thirty-Five Recollections*. Los Angeles: UCLA Tissue Typing Laboratory; 1991. p. 121-143.
93. Goodwin WE, Kaufmann JJ, Mims MM, Turner RD, Glasscock R, Goldman R, Maxwell MM. Human renal transplantation. I Clinical experience with six cases of renal homotransplantation. *J Urol*. 1963; 89:13. [PubMed: 13949129]
94. Schwartz R, Dameshek W. Drug-induced immunological tolerance. *Nature*. 1959; 183:1682. [PubMed: 13666859]
95. Schwartz R, Dameshek W. The effects of 6-mercaptopurine on homograft reactions. *J Clin Invest*. 1960; 39:952. [PubMed: 14444006]
96. Meeker W, Condie R, Weiner D, Varco RL, Good RA. Prolongation of skin homograft survival in rabbits by 6-mercaptopurine. *Proc Soc Exp Biol Med*. 1959; 102:459.
97. Calne RY. The rejection of renal homografts: inhibition in dogs by 6-mercaptopurine. *Lancet*. 1960; 1:417. [PubMed: 13807024]
98. Zukoski CF, Lee HM, Hume DM. The prolongation of functional survival of canine renal homografts by 6-mercaptopurine. *Surg Forum*. 1960; 11:470. [PubMed: 13788955]
99. Calne RY. Inhibition of the rejection of renal homografts in dogs by purine analogues. *Transplant Bull*. 1961; 28:445.
100. Calne RY, Murray JE. Inhibition of the rejection of renal homografts in dogs by Burroughs Wellcome 57-222. *Surg Forum*. 1961; 12:118. [PubMed: 13875839]
101. Calne RY, Alexandre GPJ, Murray JE. A study of the effects of drugs in prolonging survival of homologous renal transplants in dogs. *Ann NY Acad Sci*. 1962; 99:743. [PubMed: 14017936]

102. Hitchings GH, Elion GB. The chemistry and biochemistry of purine analogs. *Ann NY Acad Sci.* 1954; 60:195. [PubMed: 14350523]
103. Pierce JC, Varco RL. Induction of tolerance to a canine renal homotransplant with 6-mercaptopurine. *Lancet.* 1962; 1:781. [PubMed: 14486457]
104. Zukoski CF, Callaway JM. Adult tolerance induced by 6-methyl mercaptopurine to canine renal homografts. *Nature.* 1963; 198:706. [PubMed: 14004077]
105. Starzl TE. Experience in Renal Transplantation. Philadelphia: Saunders; 1964. Host-graft adaptation; p. 164-170.
106. Murray JE, Sheil AGR, Moseley R, Knoght PR, McGavic JD, Dammin GJ. Analysis of mechanism of immunosuppressive drugs in renal homotransplantation. *Ann Surg.* 1964; 160:449. [PubMed: 14206850]
107. Hopewell J, Calne RY, Beswick I. Three clinical cases of renal transplantation. *BMJ.* 1964; 1:411. [PubMed: 14085970]
108. Alexandre GPJ, Murray JE. Further studies of renal homotransplantation in dogs treated by combined Imuran therapy. *Surg Forum.* 1962; 13:64. [PubMed: 14011980]
109. Starzl TE, Demetris AJ, Murase N, Trucco M, Thomson AW, Rao AS. The lost chord: microchimerism. *Immunol Today.* 1996; 17:577. [PubMed: 8991290]
110. Hume DM, Magee JH, Kauffman HM Jr, Rittenbury MS, Prout GR Jr. Renal homotransplantation in man in modified recipients. *Ann Surg.* 1963; 158:608. [PubMed: 14067508]
111. Murray JE, Merrill JP, Harrison JH, Wilson RE, Dammin GJ. Prolonged survival of human-kidney homografts by immuno-suppressive drug therapy. *N Engl J Med.* 1963; 268:1315. [PubMed: 13936775]
112. Woodruff MFA, Robson JS, Nolan B, Lambie AT, Wilson TI, Clark JG. Homotransplantation of kidney in patients treated by preoperative local radiation and postoperative administration of an antimetabolite (Imuran). *Lancet.* 1963; 2:675. [PubMed: 14052033]
113. Starzl TE, Putnam CW, Halgrimson CG, Schroter GT, Martineau G, Launois B, Corman JL, Penn I, Booth AS Jr, Groth CG, Porter KA. Cyclophosphamide and whole organ transplantation in human beings. *Surg Gynecol Obstet.* 1971; 133:981. [PubMed: 4940540]
114. Starzl TE, Groth CG, Putnam CW, Corman J, Halgrimson CG, Penn I, Husberg B, Gustafsson A, Cascardo S, Geis P, Iwatsuki S. Cyclophosphamide for clinical renal and hepatic transplantation. *Transplant Proc.* 1973; 5:511. [PubMed: 4572111]
115. Starzl TE, Marchioro TL, Porter KA, Iwasaki Y, Cerilli GJ. The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. *Surg Gynecol Obstet.* 1967; 124:301. [PubMed: 4163340]
116. Medawar PB. Transplantation of tissues and organs: introduction. *Br Med Bull.* 1965; 21:97.
117. Woodruff MFA, Woodruff HG. The transplantation of normal tissues: with special reference to auto- and homotransplants of thyroid and spleen in the anterior chamber of the eye, and subcutaneously, in guinea pigs. *Philos Trans B.* 1950; 234:559.
118. Woodruff, MFA. Evidence of adaptation in homografts of normal tissue. In: Medawar, PB., editor. *Biological Problems of Grafting.* Oxford: Blackwell; 1959. p. 83-94.
119. Starzl TE. Experience in Renal Transplantation. Philadelphia: Saunders; 1964. Precepts of renal homotransplantation applied to homografting of other organs; p. 360-362.
120. Starzl TE, Kaupp HA Jr, Brock DR, Butz GW Jr, Linman JW. Homotransplantation of multiple visceral organs. *Am J Surg.* 1962; 103:219. [PubMed: 13916395]
121. Murase N, Demetris AJ, Kim DG, Todo S, Fung JJ, Starzl TE. Rejection of the multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small bowel and liver grafts. *Surgery.* 1990; 108:880. [PubMed: 2237770]
122. Murase N, Demetris AJ, Matsuzaki T, Yagihashi A, Todo S, Fung J, Starzl TE. Long survival in rats after multivisceral versus isolated small bowel allotransplantation under FK 506. *Surgery.* 1991; 110:87. [PubMed: 1714104]
123. Starzl TE, Marchioro TL, Porter KA, Taylor PD, Faris TD, Herrmann TJ, Hlad CJ, Waddell WR. Factors determining short- and long-term survival after orthotopic liver homotransplantation in the dog. *Surgery.* 1965; 58:131. [PubMed: 14305148]

124. Starzl, TE. Experience in Hepatic Transplantation. Philadelphia: Saunders; 1969. Efforts to mitigate or prevent rejection; p. 203-206.
125. Cordier G, Garnier H, Clot JP, Camplez P, Gorin JP, Clot PH, Rassinier JP, Nizza M, Levy R. La greffe de foie orthotopique chez le porc. *Mem Acad Chir (Paris)*. 1966; 92:799. [PubMed: 4869411]
126. Peacock, JH.; Terblanche, J. Orthotopic homotransplantation of the liver in the pig. In: Read, AE., editor. *The Liver*. London: Butterworth; 1967. p. 333
127. Calne RY, White HJO, Yoffa DE, Maginn RR, Binns RM, Samuel JR, Molina V. Observations of orthotopic liver transplantation in the pig. *BMJ*. 1967; 2:478. [PubMed: 5337266]
128. Calne RY, White HJO, Yoffa DE, Binns RM, Maginn RR, Herbertson RM, Millard PR, Molina VP, Davis DR. Prolonged survival of liver transplants in the pig. *BMJ*. 1967; 4:645. [PubMed: 4862477]
129. Starzl, TE. Experience in Hepatic Transplantation. Philadelphia: Saunders; 1969. Rejection in unmodified animals; p. 184
130. Hunt, AC. Pathology of liver transplantation in the pig. In: Read, AE., editor. *The Liver*. London: Butterworth; 1967. p. 337
131. Porter, KA. Pathology of the orthotopic homograft and heterograft. In: Starzl, TE., editor. *Experience in Hepatic Transplantation*. Philadelphia: Saunders; 1969. p. 427
132. Calne RY, Sells RA, Pena JR, Davis DR, Millard PR, Herbertson BM, Binns RM, Davies DAL. Induction of immunological tolerance by porcine liver allografts. *Nature*. 1969; 223:472. [PubMed: 4894426]
133. Zimmerman FA, Davies HS, Knoll PP, Gocke JM, Schmidt T. Orthotopic liver allografts in the rat. *Transplantation*. 1984; 37:406. [PubMed: 6369673]
134. Kamada N, Brons G, Davies HffS. Fully allogeneic liver grafting in rats induces a state of systemic nonreactivity to donor transplantation antigens. *Transplantation*. 1980; 29:429. [PubMed: 6990572]
135. Kamada N, Davies HffS, Roser B. Reversal of transplantation immunity by liver grafting. *Nature*. 1981; 292:840. [PubMed: 7022223]
136. Corry RJ, Winn HJ, Russell PS. Primary vascularized allografts of hearts in mice: the role of H-2D, H-2K, and non-H-2 antigens in rejection. *Transplantation*. 1973; 16:343. [PubMed: 4583148]
137. Russell PS, Chase CM, Colvin RB, Plate JMD. Kidney transplants in mice: an analysis of the immune status of mice bearing long-term H-2 incompatible transplants. *J Exp Med*. 1978; 147:1449. [PubMed: 148488]
138. Starzl, TE. Experience in Renal Transplantation. Philadelphia: Saunders; 1964. Host graft adaptation; p. 168-170.
139. Starzl, TE. Experience in Hepatic Transplantation. Philadelphia: Saunders; 1969. Efforts to mitigate or prevent rejection; p. 228-233.
140. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I Morphology, quantitation, tissue distribution. *J Exp Med*. 1973; 137:1142. [PubMed: 4573839]
141. Simonsen M. On the acquisition of tolerance by adult cells. *Ann NY Acad Sci*. 1960; 87:382. [PubMed: 14446987]
142. Burnet, FM. *The Clonal Selection Theory of Acquired Immunity*. Nashville, TN: Vanderbilt University Press; 1959. p. 59
143. Talmage DW. Immunological specificity. *Science*. 1959; 129:1649. [PubMed: 13668512]
144. Burnet FM. The new approach to immunology. *N Engl J Med*. 1961; 264:24. [PubMed: 13689160]
145. Miller JFAP. Immunological function of the thymus. *Lancet*. 1961; 2:748. [PubMed: 14474038]
146. Miller JFAP. Effect of neonatal thymectomy on the immunological responsiveness of the mouse. *Proc R Soc Lond [Biol]*. 1962; 156:415.
147. Starzl TE, Marchioro TL, Talmage DW, Waddell WR. Splenectomy and thymectomy in human renal homotransplantation. *Proc Soc Exp Biol Med*. 1963; 113:929. [PubMed: 14073145]

148. Starzl TE, Porter KA, Andres G, Groth CG, Putnam CW, Penn I, Halgrimson CG, Starkie SJ, Brettschneider L. Thymectomy and renal homotransplantation. *Clin Exp Immunol.* 1970; 6:803. [PubMed: 4920548]
149. McGregor DD, Gowans JL. Antibody response of rats depleted of lymphocytes by chronic drainage from the thoracic duct. *J Exp Med.* 1963; 117:303. [PubMed: 19867225]
150. McGregor DD, Gowans JL. Survival of homografts of skin in rats depleted of lymphocytes by chronic drainage from the thoracic duct. *Lancet.* 1964; 1:629. [PubMed: 14107928]
151. Algire GH, Weaver JM, Prehn RT. Studies on tissue homo-transplantation in mice using diffusion chamber methods. *Ann NY Acad Sci.* 1957; 64:1009. [PubMed: 13411937]
152. Starzl TE, Kaupp HA Jr, Brock DR, Linman JW. Studies on the rejection of the transplanted homologous dog liver. *Surg Gynecol Obstet.* 1961; 112:135. [PubMed: 18979656]
153. Elkinton JR. Moral problems in the use of borrowed organs, artificial and transplanted. *Ann Intern Med.* 1964; 60:309. [PubMed: 14114451]
154. Starzl TE, Marchioro TL, Rifkind D, Holmes JH, Rowlands DT Jr, Waddell WR. Factors in successful renal transplantation. *Surgery.* 1964; 56:296. [PubMed: 14174749]
155. Rifkind, D. Infectious diseases associated with renal transplantation. In: Starzl, TE., editor. *Experience in Renal Transplantation.* Philadelphia: Saunders; 1964. p. 213-238.
156. Starzl TE, Murray JE, Wilson RE, Tilney NL, Merrill JP, Cooper WC, Birtch AG, Carpenter CB, Hager EB, Dammin GJ, Harrison H. Five years experience in renal transplantation with immunosuppressive drugs. *Ann Surg.* 1968; 168:416. [PubMed: 4175449]
157. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. *Transplant Proc.* 1969; 1:106. [PubMed: 4944206]
158. Starzl TE, Penn I, Putnam CW, Groth CG, Halgrimson CG. Iatrogenic alterations of immunologic surveillance in man and their influence on malignancy. *Transplant Rev.* 1971; 7:112. [PubMed: 4401720]
159. Hill RB Jr, Rowlands DT, Rifkind D. Infectious pulmonary disease in patients receiving immunosuppressive therapy for organ transplantation. *N Engl J Med.* 1964; 271:1021. [PubMed: 14195753]
160. Rifkind D, Starzl TE, Marchioro TL, Waddell WR, Rowlands DT Jr, Hill RB Jr. Transplantation pneumonia. *JAMA.* 1964; 189:808. [PubMed: 14172276]
161. Van Thiel D, Iqbal M, Jain A, Fung J, Todo S, Starzl TE. Gastrointestinal and metabolic problems associated with immuno-suppression with either cyclosporine or FK 506 in liver transplantation. *Transplant Proc.* 1990; 22:37. [PubMed: 1689893]
162. Iwasaki Y, Porter KA, Amend JR, Marchioro TL, Zuhke V, Starzl TE. The preparation and testing of horse antidog and anti-human antilymphoid plasma or serum and its protein fractions. *Surg Gynecol Obstet.* 1967; 124:1. [PubMed: 6016025]
163. Woodruff MFA, Anderson NF. Effect of lymphocyte depletion by thoracic duct fistula and administration of anti-lymphocytic serum on the survival of skin homografts in rats. *Nature.* 1963; 200:702. [PubMed: 14109976]
164. Franksson C, Blomstrand R. Drainage of the thoracic lymph duct during homologous kidney transplantation in man. *Scand J Urol Nephrol.* 1967; 1:123.
165. Starzl TE, Weil R III, Koep LJ, Iwaki Y, Terasaki PI, Schroter GPJ. Thoracic duct drainage before and after cadaveric kidney transplantation. *Surg Gynecol Obstet.* 1979; 149:815. [PubMed: 388702]
166. Starzl TE, Klintmalm GBG, Iwatsuki S, Schroter G, Weil R III. Late follow-up after thoracic duct drainage in cadaveric renal transplantation. *Surg Gynecol Obstet.* 1981; 153:377. [PubMed: 7022708]
167. Slavin S, Reitz B, Bieber CP, Kaplan HS, Strober S. Transplantation tolerance in adult rats using total lymphoid irradiation (TLI): permanent survival of skin, heart, and marrow allografts. *J Exp Med.* 1978; 147:700. [PubMed: 147301]
168. Najarian JS, Ferguson RM, Sutherland DER, Slavin S, Kim T, Kersey T, Simmons RL. Fractionated total lymphoid irradiation as preparative immunosuppression in high-risk renal transplantation. *Ann Surg.* 1982; 196:442. [PubMed: 6812511]

169. Myburgh AJ, Smit AJ, Meyers MA, Botha JR, Browde S, Thomson PD. Total lymphoid irradiation in renal transplantation. *World J Surg.* 1986; 10:369. [PubMed: 3524025]
170. Metchnikoff I. Etude sur la resorption des cellules. *Ann Inst Pasteur.* 1899; 13:737.
171. Inderbitzen, T. Histamine in allergic responses of the skin. In: Shafer, JH.; LeGrippe, GA.; Chase, MW., editors. *Henry Ford Hospital International Symposium on Mechanisms of Hypersensitivity.* Boston: Little, Brown; 1959. p. 493-499.
172. Waksman BY, Arbouys S, Arnason BG. The use of specific "lymphocyte" antisera to inhibit hypersensitive reactions of the "delayed" type. *J Exp Med.* 1961; 114:997. [PubMed: 14004486]
173. Levey RH, Medawar PB. Nature and mode of action of antilymphocytic antiserum. *Proc Natl Acad Sci USA.* 1966; 56:1130. [PubMed: 5339289]
174. Monaco AP, Wood ML, Russell PS. Adult thymectomy: effect on recovery from immunologic depression in mice. *Science.* 1965; 149:432. [PubMed: 17809411]
175. Monaco AP, Wood ML, Russell PS. Studies of heterologous antilymphocyte serum in mice. III Immunologic tolerance and chimerism produced across the H-2 locus with adult thymectomy and antilymphocyte serum. *Ann NY Acad Sci.* 1966; 129:190.
176. Najarian JS, Simmons RL, Gewurz H, Moberg A, Merkel F, Moore GA. Anti-serum to cultured human lymphoblasts: preparation, purification and immunosuppressive properties in man. *Ann Surg.* 1969; 170:617. [PubMed: 4186508]
177. Kohler G, Milstein C. Continuous culture of fused cells secreting antibody of predefined specificity. *Nature.* 1975; 256:495. [PubMed: 1172191]
178. Cosimi AB, Colvin RB, Burton RC, Rubin RH, Goldstein G, Kung PC, Hansen WP, Delmonico FL, Russell PS. Use of monoclonal antibodies to T-cell subsets for immunological monitoring and treatment in recipients of renal allografts. *N Engl J Med.* 1981; 305:308. [PubMed: 6454075]
179. Dreyfuss M, Harri E, Hofmann H, Kobel H, Pache W, Tschertter H. Cyclosporin A and C; new metabolites from *Trichoderma polysporum* (Link ex Pers) Rifai. *Eur J Appl Microbiol.* 1976; 3:125.
180. Ruegger A, Kuhn M, Lichti H, Loosli HR, Huguenin R, Quinquerez C, von Wartburg A. Cyclosporin A, ein immunosuppressiv wirksamer Peptidmetabolit aus *Trichoderma polysporum* (Link ex Pers) Rifai. *Helv Chim Acta.* 1976; 59:1075. [PubMed: 950308]
181. Petcher TJ, Weber HP, Ruegger A. Crystal and molecular structure of an iodo-derivative of the cyclic underceptopeptide cyclosporin A. *Helv Chim Acta.* 1976; 59:1480. [PubMed: 931750]
182. Borel JF. Comparative study of in vitro and in vivo drug effects on cell-mediated cytotoxicity. *Immunology.* 1976; 31:631. [PubMed: 824198]
183. Borel JF, Feurer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A; a new antilymphocytic agent. *Agents Actions.* 1976; 6:468. [PubMed: 8969]
184. Borel JF, Feurer C, Magnee C, Stahelin H. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. *Immunology.* 1977; 32:1017. [PubMed: 328380]
185. Kostakis AJ, White DJG, Calne RY. Prolongation of rat heart allograft survival by cyclosporin A. *Int Res Commun Syst Med Sci.* 1977; 5:280.
186. Calne RY, White DJG. Cyclosporin A; a powerful immunosuppressant in dogs with renal allografts. *Int Res Commun Syst Med Sci.* 1977; 5:595.
187. Calne RY, White DJG, Rolles K, Smith DP, Herbertson BM. Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A. *Lancet.* 1978; 1:1183. [PubMed: 77948]
188. Calne RY, White DJG, Pentlow BD, Rolles K, Syrakos T, Ohtawa T, Smith DP, McMaster P, Evans DB, Herbertson BM, Thiru S. Cyclosporin A; preliminary observations in dogs with pancreatic duodenal allografts and patients with cadaveric renal transplants. *Transplant Proc.* 1979; 11:860. [PubMed: 377719]
189. Green CJ, Allison AC. Extensive prolongation of rabbit kidney allograft survival after short-term cyclosporin A treatment. *Lancet.* 1978; 1:1182. [PubMed: 77947]
190. Calne RY, White DJG, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, Pentlow BD, Rolles K. Cyclosporin A in patients receiving renal allografts from cadaver donors. *Lancet.* 1978; 2:1323. [PubMed: 82836]

191. Calne RY, Rolles K, White DJG, Thiru S, Evans DB, Mc-Master P, Dunn DC, Craddock GN, Henderson RG, Aziz S, Lewis P. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs; 32 kidneys, 2 pancreases, and 2 livers. *Lancet*. 1979; 2:1033. [PubMed: 91781]
192. Starzl TE, Weil R III, Iwatsuki S, Klintmalm G, Schroter GPJ, Koep LJ, Iwaki Y, Terasaki PI, Porter KA. The use of cyclosporin A and prednisone in cadaver kidney transplantation. *Surg Gynecol Obstet*. 1980; 151:17. [PubMed: 6992310]
193. Starzl TE, Klintmalm GBG, Porter KA, Iwatsuki S, Schroter GPJ. Liver transplantation with use of cyclosporin A and prednisone. *N Engl J Med*. 1981; 305:266. [PubMed: 7017414]
194. Reitz BA, Wallwork JL, Hunt SA, Pennock JL, Billingham RE, Oyer PE, Stinson EB, Shumway NE. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. *N Engl J Med*. 1982; 306:557. [PubMed: 6799824]
195. Griffith BP, Hardesty RL, Deeb GM, Starzl TE, Bahnson HT. Cardiac transplantation with cyclosporin A and prednisone. *Ann Surg*. 1982; 196:324. [PubMed: 7051996]
196. Cooper J. The evolution of techniques and indications for lung transplantation. *Ann Surg*. 1990; 212:249. [PubMed: 2204316]
197. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramanan R, Jain A. FK 506 for human liver, kidney and pancreas transplantation. *Lancet*. 1989; 2:1000. [PubMed: 2478846]
198. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, Goto T, Okuhara M, Kohsaka M, Aoki H, Ochiai T. FK506, a novel immunosuppressant isolated from *Streptomyces*. II Immunosuppressive effect of FK-506 in vitro. *J Antibiot (Tokyo)*. 1987; 40:1256. [PubMed: 2445722]
199. Ochiai T, Nakajima K, Nagata M, Suzuki T, Asano T, Uematsu T, Goto T, Hori S, Kinmochi T, Nakagouri T, Isono K. Effect of a new immunosuppressive agent, FK506, on heterotopic allotransplantation in the rat. *Transplant Proc*. 1987; 19:1284. [PubMed: 2484094]
200. Murase N, Todo S, Lee P-H, Lai HS, Chapman F, Nalesnik MA, Makowka L, Starzl TE. Heterotopic heart transplantation in the rat under FK-506 alone or with cyclosporine. *Transplant Proc*. 1987; 19:71. [PubMed: 2445081]
201. Lee P, Murase N, Todo S, Makowka L, Starzl T. The immunosuppressive effects of FK 506 in rats receiving heterotopic cardiac allografts. *Surg Res Commun*. 1987; 1:325.
202. Todo S, Podesta L, ChapChap P, Kahn D, Pan C-E, Ueda Y, Okuda K, Imventarza O, Casavilla A, Demetris AJ, Makowka L, Starzl TE. Orthotopic liver transplantation in dogs receiving FK-506. *Transplant Proc*. 1987; 19:64. [PubMed: 2445079]
203. Todo S, Ueda Y, Demetris JA, Imventarza O, Nalesnik M, Venkataramanan R, Makowka L, Starzl TE. Immunosuppression of canine, monkey, and baboon allografts by FK 506 with special reference to synergism with other drugs, and to tolerance induction. *Surgery*. 1988; 104:239. [PubMed: 2456627]
204. Todo S, Demetris A, Ueda Y, Imventarza O, Cadoff E, Zeevi A, Starzl TE. Renal transplantation in baboons under FK 506. *Surgery*. 1989; 106:444. [PubMed: 2474865]
205. Fung JJ, Todo S, Jain A, McCauley J, Alessiani M, Scotti C, Starzl TE. Conversion of liver allograft recipients with cyclosporine related complications from cyclosporine to FK 506. *Transplant Proc*. 1990; 22:6. [PubMed: 1689901]
206. Armitage JM, Kormos RL, Griffith BP, Hardesty RL, Fricker FJ, Stuart RS, Marrone GC, Todo S, Fung J, Starzl TE. The clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. *Transplant Proc*. 1991; 23:1149. [PubMed: 1703336]
207. Todo S, Fung JJ, Starzl TE, Tzakis A, Demetris AJ, Kormos R, Jain A, Alessiani M, Takaya S. Liver, kidney, and thoracic organ transplantation under FK 506. *Ann Surg*. 1990; 212:295. [PubMed: 1697743]
208. Starzl TE, Fung J, Jordan M, Shapiro R, Tzakis A, McCauley J, Johnston J, Iwaki Y, Jain A, Alessiani M, Todo S. Kidney transplantation under FK 506. *JAMA*. 1990; 264:63. [PubMed: 1693970]
209. Starzl TE, Donner A, Eliasziw M, Stitt L, Meier P, Fung JJ, McMichael JP, Todo S. Randomized trial of multi-center liver transplant trials. *Lancet*. 1995; 346:1346. [PubMed: 7475777]

210. Fung JJ, Todo S, Tzakis A, Demetris A, Jain A, Abu-Elmagd K, Alessiani M, Starzl TE. Conversion of liver allograft recipients from cyclosporine to FK506-based immunosuppression: benefits and pitfalls. *Transplant Proc.* 1991; 23:14. [PubMed: 1703682]
211. Fung JJ, Todo S, Jain A, Demetris AJ, McMichael JP, Starzl TE. The Pittsburgh randomized trial of tacrolimus versus cyclosporine for liver transplantation. *J Am Coll Surg.* 1996; 183:117. [PubMed: 8696542]
212. Neuhaus P, Pichlmayr R, Williams R. European FK 506 Multi-centre Liver Study Group. Randomised trial comparing tacrolimus (FK 506) and cyclosporin in prevention of liver allograft rejection. *Lancet.* 1994; 344:423. [PubMed: 7520105]
213. Klintmalm G. US Multicenter FK 506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immuno-suppression in liver transplantation. *N Engl J Med.* 1994; 331:1110. [PubMed: 7523946]
214. Starzl TE, Abu-Elmagd K, Tzakis A, Fung JJ, Porter KA, Todo S. Selected topics on FK 506: With special references to rescue of extrahepatic whole organ grafts, transplantation of “forbidden organs”, side effects, mechanisms, and practical pharmacokinetics. *Transplant Proc.* 1991; 23:914. [PubMed: 1703351]
215. Todo S, Tzakis AG, Abu-Elmagd K, Reyes J, Nakamura K, Casavilla A, Selby R, Nour BM, Wright H, Fung JJ, Demetris AJ, Van Thiel DH, Starzl TE. Intestinal transplantation in composite visceral grafts or alone. *Ann Surg.* 1992; 216:223. [PubMed: 1384443]
216. Todo S, Tzakis AG, Abu-Elmagd K, Reyes J, Fung JJ, Casavilla A, Nakamura K, Yagihashi A, Jain A, Murase N, Iwaki Y, Demetris AJ, Van Thiel D, Starzl TE. Cadaveric small bowel and small bowel–liver transplantation in humans. *Transplantation.* 1992; 53:369. [PubMed: 1738932]
217. Starzl TE, Brittain RS, Stonington OG, Coppinger RW, Waddell WR. Renal transplantation in identical twins. *Arch Surg.* 1963; 86:600. [PubMed: 13983517]
218. Owens TC, Prevedel AE, Swan H. Prolonged experimental occlusion of thoracic aorta during hypothermia. *Arch Surg.* 1955; 70:95.
219. Starzl TE. Experience in Renal Transplantation. Philadelphia: Saunders; 1964. p. 68-71.
220. Marchioro TL, Huntley RT, Waddell WR, Starzl TE. Extra-corporeal perfusion for obtaining postmortem homografts. *Surgery.* 1963; 54:900. [PubMed: 14087127]
221. Ackerman JR, Snell ME. Cadaveric renal transplantation. *Br J Urol.* 1968; 40:515. [PubMed: 4879056]
222. Merkel FK, Jonasson O, Bergan JJ. Procurement of cadaver donor organs: evisceration techniques. *Transplant Proc.* 1972; 4:585. [PubMed: 4645813]
223. Starzl TE, Hakala TR, Shaw BW Jr, Hardesty RL, Rosenthal TE, Griffith BP, Iwatsuki S, Bahnson HT. A flexible procedure for multiple cadaveric organ procurement. *Surg Gynecol Obstet.* 1984; 158:223. [PubMed: 6367113]
224. Starzl TE, Miller C, Broznick B, Makowka L. An improved technique for multiple organ harvesting. *Surg Gynecol Obstet.* 1987; 165:343. [PubMed: 3310285]
225. Carrel A.; Lindbergh, CA. *The Culture of Organs.* New York: Hoeber; 1938.
226. Ackerman JR, Barnard CN. A report on the successful storage of kidneys. *Br J Surg.* 1966; 53:525. [PubMed: 5327849]
227. Brettschneider L, Daloze PM, Huguet C, Porter KA, Groth DG, Kashiwagi N, Hutchison DE, Starzl TE. The use of combined preservation techniques for extended storage of orthotopic liver homografts. *Surg Gynecol Obstet.* 1968; 126:263. [PubMed: 21188295]
228. Belzer FO, Ashby BS, Dunphy JE. 24-Hour and 72 hour preservation of canine kidneys. *Lancet.* 1967; 2:536. [PubMed: 4166894]
229. Collins GM, Bravo-Shugartman M, Terasaki PI. Kidney preservation for transportation: initial perfusion and 30 hours ice storage. *Lancet.* 1969; 2:1219. [PubMed: 4187813]
230. Schalm, SW. Thesis. University of Leyden; Holland: 1968. A simple and clinically applicable method for the preservation of a liver homograft.
231. Benichou J, Halgrimson CG, Weil R III, Koep LJ, Starzl TE. Canine and human liver preservation for 6–18 hours by cold infusion. *Transplantation.* 1977; 24:407. [PubMed: 339435]

232. Wall WJ, Calne RY, Herbertson BM, Baker PG, Smith DP, Underwood J, Kostakis A, Williams R. Simple hypothermic preservation for transporting human livers long distances for transplantation. *Transplantation*. 1977; 23:210. [PubMed: 324041]
233. Jamieson NV, Sundberg R, Lindell S, Laravuso R, Kalayoglu M, Southard JH, Belzer FO. Successful 24- to 30-hour preservation of the canine liver: a preliminary report. *Transplant Proc*. 1988; 29(Suppl. 1):945.
234. Kalayoglu M, Sollinger WH, Stratta RJ, D'Alessandro AM, Hoffman RM, Pirsch JD, Belzer FO. Extended preservation of the liver for clinical transplantation. *Lancet*. 1988; 1:617. [PubMed: 2894550]
235. Todo S, Nery J, Yanaga K, Podesta L, Gordon RD, Starzl TE. Extended preservation of human liver grafts with UW solution. *JAMA*. 1989; 261:711. [PubMed: 2642982]
236. Hoffman B, Sollinger H, Kalayoglu M, Belzer FO. Use of UW solution for kidney transplantation. *Transplantation*. 1988; 46:338. [PubMed: 3043790]
237. Wahlberg JA, Love R, Landegaard L, Southard JH, Belzer FO. 72-Hour preservation of the canine pancreas. *Transplantation*. 1987; 43:5. [PubMed: 3541322]
238. Ploeg RJ, Goossens D, McAnulty JF, Southard JH, Belzer FO. Successful 72-hour cold storage of dog kidneys with UW solution. *Transplantation*. 1988; 46:191. [PubMed: 3043775]
239. Ueda Y, Todo S, Imventarza O, Furukawa H, Oks A, Wu YM, Oguma S, Starzl TE. The UW solution for canine kidney preservation: its specific effect on renal hemodynamics and microvasculature. *Transplantation*. 1989; 48:913. [PubMed: 2595778]
240. Belzer FO, Southard JH. Principles of solid-organ preservation by cold storage. *Transplantation*. 1988; 45:673. [PubMed: 3282347]
241. Todo S, Podesta L, Ueda Y, Imventarza O, Casavilla A, Oks A, Okuda K, Nalesnik M, Venkataramanan R, Starzl TE. A comparison of UW with other solutions for liver preservation in dogs. *Clin Transplant*. 1989; 3:253. [PubMed: 21151798]
242. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw BW Jr, Hardesty RL, Atchison RW, Jaffe R, Bahnson HT. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. *Lancet*. 1984; 1:583. [PubMed: 6142304]
243. Starzl TE. The mother lode of liver transplantation: with particular reference to our new journal. *Liver Transplant Surg*. 1998; 4:1.
244. Starzl TE, Marchioro TL, Rowlands DT Jr, Kirkpatrick CH, Wilson WEC, Rifkind D, Waddell WR. Immunosuppression after experimental and clinical homotransplantation of the liver. *Ann Surg*. 1964; 160:411. [PubMed: 14206848]
245. Marchioro TL, Porter KA, Dickinson TC, Faris TD, Starzl TE. Physiologic requirements for auxiliary liver homotransplantation. *Surg Gynecol Obstet*. 1965; 121:17. [PubMed: 14314095]
246. Starzl TE, Francavilla A, Halgrimson CG, Francavilla FR, Porter KA, Brown TH, Putnam CW. The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. *Surg Gynecol Obstet*. 1973; 137:179. [PubMed: 4353133]
247. Starzl TE, Porter KA, Putnam CW. Intraportal insulin protects from the liver injury of portacaval shunt in dogs. *Lancet*. 1975; 2:1241. [PubMed: 53727]
248. Francavilla A, Hagiya M, Porter KA, Polimeno L, Ihara I, Starzl TE. Augmenter of liver regeneration (ALR): its place in the universe of hepatic growth factors. *Hepatology*. 1994; 20:747. [PubMed: 8076931]
249. Starzl TE, Jones AF, Terblanche J, Usui S, Porter KA, Mazzoni G. Growth-stimulating factor in regenerating canine liver. *Lancet*. 1979; 1:127. [PubMed: 84151]
250. Hagiya M, Francavilla A, Polimeno L, Ihara I, Sakai H, Seki T, Shimonishi M, Porter KA, Starzl TE. Cloning and sequence analysis of the rat augmenter of liver regeneration (ALR) gene: expression of biology active recombinant ALR and demonstration of tissue distribution. *Proc Natl Acad Sci USA*. 1994; 91:8142. [PubMed: 8058770]
251. Giorda R, Hagiya M, Seki T, Shimonishi M, Sakai H, Michaelson J, Francavilla A, Starzl TE, Trucco M. Analysis of the structure and expression of the ALR gene. *Mol Med*. 1996; 2:97. [PubMed: 8900538]

252. Starzl TE, Demetris AJ, Van Thiel DH. Medical progress: liver transplantation. *N Engl J Med*. 1989; 321:1014. [PubMed: 2674716]
253. Starzl TE. *The Puzzle People*. Pittsburgh: University of Pittsburgh Press; 1992. The little drummer girls; p. 318-333.
254. Snell GD. Methods for the study of histocompatibility genes. *J Genet*. 1948; 49:87. [PubMed: 18893744]
255. Brent L. *A History of Transplantation Immunology*. San Diego: Academic; 1997. Immunogenetics: histocompatibility antigens—genetics, structure and function; p. 131-182.
256. Dausset J. Isoleuco-anticorps. *Acta Haematol*. 1958; 20:156. [PubMed: 13582558]
257. Van Rood JJ, Eernisses JG, van Leeuwen A. Leucocyte antibodies in sera from pregnant women. *Nature*. 1958; 181:1735. [PubMed: 13566127]
258. Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. *Nature*. 1964; 204:998. [PubMed: 14248725]
259. Starzl TE, Marchioro TL, Holmes JH, Hermann G, Brittain RS, Stonington OH, Talmage DW, Waddell WR. Renal homografts in patients with major donor-recipient blood group incompatibilities [addendum]. *Surgery*. 1964; 55:195. [PubMed: 14121762]
260. Starzl TE, Ishikawa M, Putnam CW, Porter KA, Picache R, Husberg BS, Halgrimson CG, Schroter G. Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. *Transplant Proc*. 1974; 6:129. [PubMed: 4373884]
261. Rapaport FT, Dausset J, Legrand L, Barge A, Lawrence HS, Converse JM. Erythrocytes in human transplantation: effects of pretreatment with ABO group-specific antigens. *J Clin Invest*. 1968; 47:2202.
262. Terasaki PI, Marchioro TL, Starzl TE. *Histocompatibility Testing*. Washington, DC: National Academy of Sciences–National Research Council; 1965. Sero-typing of human lymphocyte antigens: preliminary trials on long-term kidney homograft survivors; p. 83-96.
263. Kissmeyer-Nielsen F, Olsen S, Peterson VP, Fieldborg O. Hyperacute rejection of kidney allografts associated with preexisting humoral antibodies against donor cells. *Lancet*. 1966; 2:662. [PubMed: 4162350]
264. Williams GM, Hume DM, Hudson RP, Morris PJ, Kano K, Milgrom F. “Hyperacute” renal-homograft rejection in man. *N Engl J Med*. 1968; 279:611. [PubMed: 4174539]
265. Starzl TE, Lerner RA, Dixon FJ, Groth CG, Brettschneider L, Terasaki PI. Shwartzman reaction after human renal transplantation. *N Engl J Med*. 1968; 278:642. [PubMed: 4866352]
266. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. *N Engl J Med*. 1969; 280:735. [PubMed: 4886455]
267. Simpson KM, Bunch DL, Amemiya H, Boehmig HJ, Wilson CB, Dixon FJ, Coburg AJ. Humoral antibodies and coagulation mechanisms in the accelerated or hyperacute rejection of renal homografts in sensitized canine recipients. *Surgery*. 1970; 68:77. [PubMed: 4393142]
268. Boehmig HJ, Giles GR, Amemiya H, Wilson CB, Coburg AJ, Genton E, Bunch DL, Dixon FJ, Starzl TE. Hyperacute rejection of renal homografts: with particular reference to coagulation changes, humoral antibodies, and formed blood elements. *Transplant Proc*. 1971; 3:1105. [PubMed: 4944050]
269. Starzl TE, Boehmig HJ, Amemiya H, Wilson CB, Dixon FJ, Giles GR, Simpson KM, Halgrimson CG. Clotting changes, including disseminated intravascular coagulation, during rapid renal-homograft rejection. *N Engl J Med*. 1970; 283:383. [PubMed: 4193841]
270. Myburgh JA, Cohen I, Gecelther L, Meyers AM, Abrahams C, Furman KI, Goldberg B, van Blerk PJ. Hyperacute rejection in human-kidney allografts Shwartzman or Arthus reaction? *N Engl J Med*. 1969; 281:131. [PubMed: 4239833]
271. Cerilli J, Brasile L, Galouzis T, Lempert N, Clark J. The vascular endothelial cell antigen system. *Transplantation*. 1985; 39:286. [PubMed: 3919480]
272. Brasile L, Zerbe T, Rabin B, Clarke J, Abrahams A, Cerilli J. Identification of the antibody to vascular endothelial cells in patients undergoing cardiac transplantation. *Transplantation*. 1985; 40:672. [PubMed: 3907041]

273. Knechtle SJ, Halperin EC, Bollinger RR. Xenograft survival in two species combinations using total-lymphoid irradiation and cyclosporin. *Transplantation*. 1987; 43:173. [PubMed: 3544372]
274. Gubernatis G, Lauchart W, Jonker M, Steinhoff G, Bornnscheuer A, Neuhaus P, Vanes AA, Kemnitz J, Wonigeit K, Pichlmayr R. Signs of hyperacute rejection of liver grafts of rhesus monkeys after donor-specific presensitization. *Transplant Proc*. 1987; 19:1082. [PubMed: 3274282]
275. Merion RM, Colletti LM. Demonstration of hyperacute rejection (HAR) in outbred large animal model of liver transplantation (LTX). *Transplantation*. 1990; 49:861. [PubMed: 2139985]
276. Takaya S, Bronsther O, Iwaki Y, Nakamura K, Abu-Elmagd K, Yagihashi A, Demetris AJ, Kobayashi M, Todo S, Tzakis AG, Fung JJ, Starzl TE. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. *Transplantation*. 1992; 53:400. [PubMed: 1371195]
277. Starzl TE, Demetris AJ, Todo S, Kang Y, Tzakis A, Duquesnoy R, Makowka L, Banner B, Concepcion W, Porter KA. Evidence for hyperacute rejection of human liver grafts: the case of the canary kidneys. *Clin Transplant*. 1989; 3:37. [PubMed: 21151799]
278. Starzl, TE. *The Puzzle People*. Pittsburgh: University of Pittsburgh Press; 1992. Tissue matching; p. 118-124.
279. Brent, L. *A History of Transplantation Immunology*. London: Academic; 1997. Immunogenetics: histocompatibility antigens: structure and function; p. 153-159.
280. Starzl TE, Marchioro TL, Terasaki PI, Porter KA, Faris TD, Herrmann TJ, Vredevoe DL, Hutt MP, Ogden DA, Waddell WR. Chronic survival after human renal homotransplantations: lymphocyte-antigen matching, pathology and influence of thymectomy. *Ann Surg*. 1965; 162:749. [PubMed: 5319400]
281. Terasaki PI, Vredevoe DL, Mickey MR, Porter KA, Marchioro TL, Faris TD, Starzl TE. Serotyping for homotransplantation. VI Selection of kidney donors for thirty-two recipients. *Ann NY Acad Sci*. 1966; 129:500. [PubMed: 21165168]
282. Rapaport FT, Lawrence HS, Thomas L, Converse JM, Tillett WS, Mulholland JH. Cross-reactions to skin homografts in man. *J Clin Invest*. 1962; 41:2166. [PubMed: 13973073]
283. Dausset, J.; Rapaport, FT. The Hu-1 system of human histocompatibility. In: Rapaport, FT.; Dausset, J., editors. *Human Transplantation*. Orlando, FL: Grune & Stratton; 1968. p. 369
284. Rapaport FT, Dausset J. Behavior of HLA-compatible and incompatible skin allografts in human recipients preimmunized with pooled leukocyte extracts obtained from randomly selected donors. *Transplantation*. 1983; 36:592. [PubMed: 6356525]
285. Starzl TE, Porter KA, Andres G, Halgrimson CG, Hurwitz R, Giles G, Terasaki PI, Penn I, Schroter GT, Lilly J, Starkie SJ, Putnam CW. Long-term survival after renal transplantation in humans: with special reference to histocompatibility matching, thymectomy, homograft glomerulonephritis, heterologous ALG, and recipient malignancy. *Ann Surg*. 1970; 172:437. [PubMed: 4918003]
286. Mickey MR, Kreisler M, Albert ED, Tanaka N, Terasaki PI. Analysis of HL-A incompatibility in human renal transplants. *Tissue Antigens*. 1971; 1:57. [PubMed: 4949393]
287. Starzl TE, Eliasziw M, Gjertson M, Terasaki PI, Fung JJ, Trucco M, Martell J, McMichael J, Shapiro R, Donner A. HLA and cross reactive antigen group (CREG) matching for cadaver kidney allocation. *Transplantation*. 1997; 64:983. [PubMed: 9381546]
288. Starzl, TE.; Demetris, AJ.; Murase, N.; Ricordi, C.; Trucco, M. The enigma of graft acceptance. In: Shumway, SJ.; Shumway, NE., editors. *Thoracic Transplantation*. Oxford: Blackwell; 1995. p. 452-470.
289. Starzl TE, Demetris AJ, Trucco M, Ramos H, Zeevi A, Rudert WA, Kocova M, Ricordi C, Ildstad S, Murase N. Systemic chimerism in human female recipients of male livers. *Lancet*. 1992; 340:876. [PubMed: 1357298]
290. Starzl TE, Demetris AJ, Trucco M, Zeevi A, Ramos H, Terasaki P, Rudert WA, Kocova M, Ricordi C, Ildstad S, Murase N. Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. *Transplantation*. 1993; 55:1272. [PubMed: 8516813]
291. Starzl TE, Demetris AJ, Trucco M, Ricordi C, Ildstad S, Terasaki PI, Murase N, Kendall RS, Kocoua M, Rudert WA, Zeevi A, Van Thiel D. Chimerism after liver transplantation for type IV

- glycogen storage disease and type I Gaucher's disease. *N Engl J Med.* 1993; 328:745. [PubMed: 8437594]
292. Demetris AJ, Murase N, Starzl TE. Donor dendritic cells after liver and heart allotransplantation under short-term immunosuppression. *Lancet.* 1992; 339:1610.
 293. Demetris AJ, Murase N, Fujisaki S, Fung JJ, Rao AS, Starzl TE. Hematolymphoid cell trafficking, microchimerism, and GVHD reactions after liver, bone marrow, and heart transplantation. *Transplant Proc.* 1993; 25:3337. [PubMed: 7505503]
 294. Qian S, Demetris AJ, Murase N, Rao AS, Fung JJ, Starzl TE. Murine liver allograft transplantation: tolerance and donor cell chimerism. *Hepatology.* 1994; 19:916. [PubMed: 8138266]
 295. Murase N, Starzl TE, Tanabe M, Fujisaki S, Miyazawa H, Ye Q, Delaney CP, Fung JJ, Demetris AJ. Variable chimerism, graft versus host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. *Transplantation.* 1995; 60:158. [PubMed: 7624958]
 296. Michie D, Woodruff MFA, Zeiss IM. An investigation of immunological tolerance based on chimera analysis. *Immunology.* 1961; 4:413. [PubMed: 14473459]
 297. Simonsen M. Graft versus host reactions: their natural history, and applicability as tools of research. *Prog Allergy.* 1962; 6:349. [PubMed: 14037719]
 298. Bain B, Vas MR, Lowenstein L. The development of large immature mononuclear cells in mixed leukocyte cultures. *Blood.* 1964; 23:108. [PubMed: 14107045]
 299. Bach F, Hirschhorn K. Lymphocyte interaction: a potential histo-compatibility test in vitro. *Science.* 1964; 143:813. [PubMed: 14088078]
 300. Martinez C, Shapiro F, Good RA. Essential duration of parabiosis and development of tolerance to skin homografts in mice. *Proc Soc Exp Biol Med.* 1960; 104:256. [PubMed: 14421787]
 301. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. *Nature.* 1984; 307:168. [PubMed: 6361574]
 302. Thomas J, Carver M, Cunningham P, Park K, Gonder J, Thomas F. Promotion of incompatible allograft acceptance in rhesus monkeys given posttransplant antithymocyte globulin and donor bone marrow. I In vivo parameters and immunohistologic evidence suggesting microchimerism. *Transplantation.* 1987; 43:332. [PubMed: 3103273]
 303. Przepiorka D, Thomas ED, Durham DM, Fisher L. Use of a probe to repeat sequence of the Y chromosome for detection of host cells in peripheral blood of bone marrow transplant recipients. *Am J Clin Pathol.* 1991; 95:201. [PubMed: 1992610]
 304. Lawrence HS. Homograft sensitivity: an expression of the immunologic origins and consequences of individuality. *Physiol Rev.* 1959; 39:811. [PubMed: 14414715]
 305. Medawar PB. The immunology of transplantation. *Harvey Lect.* 1957; 52:144.
 306. Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syn-geneic or semi-allogeneic system. *Nature.* 1974; 248:701. [PubMed: 4133807]
 307. Zinkernagel RM. Restriction by H-2 gene complex of transfer of cell-mediated immunity to *Listeria monocytogenes*. *Nature.* 1974; 251:230. [PubMed: 4214309]
 308. Doherty PC, Zinkernagel RM. A biological role for the major histocompatibility antigens. *Lancet.* 1975; 1:1406. [PubMed: 49564]
 309. Zinkernagel RM, Doherty PC. The discovery of MHC restriction. *Immunol Today.* 1997; 18:14. [PubMed: 9018968]
 310. Zinkernagel RM. Immunology taught by viruses. *Science.* 1996; 271:173. [PubMed: 8539616]
 311. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H. Antigen localization regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. *Immunol Rev.* 1997; 156:199. [PubMed: 9176709]
 312. Starzl TE, Rao AS, Murase N, Fung J, Demetris AJ. Will xenotransplantation ever be feasible? *J Am Coll Surg.* 1998; 186:383. [PubMed: 9544950]

313. Starzl J, Silverstein AM. Development aspects of immunity. *Adv Immunol.* 1967; 6:337. [PubMed: 4860248]
314. Matzinger P. Tolerance, danger, and the extended family. *Annu Rev Immunol.* 1994; 12:991. [PubMed: 8011301]
315. Ridge JP, Fuchs EJ, Matzinger P. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. *Science.* 1996; 271:1723. [PubMed: 8596932]

Fig. 1. Chimerism in freemartin (fraternal twins) described by Owen [11]. Cross-tolerance to formed blood elements followed intrauterine circulatory exchange in dizygotic twins. Mutual tolerance to skin grafts was later proved by Anderson et al. with Medawar [12]. (From Starzl and Butz [13], with permission.)

Fig. 2. 1969 hypothesis of allograft acceptance by clonal exhaustion. Antigen presentation was depicted via the macrophages rather than by the dendritic cells (which had not yet been described). A gap in this hypothesis was the failure to stipulate the location of the immune activation. (From Starzl [139], with permission.)

Fig. 3. Diffusion chamber used in studies by Algire et al. [151], from which they concluded that lymphocytes were the cellular agents of allograft rejection. (From Starzl and Butz [13], with permission.)

Fig. 4. Possible mechanisms of simultaneous loss of host reactivity to specific strains of endogenous bacteria and to the alien renal tissue. (From Starzl et al. [154], with permission.)

Fig. 5.

Three eras of orthotopic liver transplantation at the Universities of Colorado (1963–1980) and Pittsburgh (1981–1993), defined by azathioprine-, cyclosporine-, and FK 506 (tacrolimus)-based immune suppression. The same stepwise improvement was seen with all organs. **Top.** Patient survival. **Bottom.** Graft survival. The rate here was about 10% lower than that for patient survival in both the cyclosporine (1980–1989) and tacrolimus eras (1989–1993) because of effective retransplantation, an option that did not exist previously. AZA: azathioprine; CYA: cyclosporine; TAC: tacrolimus.

Fig. 6.

Technique of extracorporeal perfusion with a heart-lung machine described by Marchioro et al. [220]. Catheters are inserted via the femoral vessels into the aorta and vena cava as soon as possible after death. The extracorporeal circuit is primed with a glucose or electrolyte solution to which procaine and heparin are added. The cadaver is thus anticoagulated with the first surge of the pump. Temperature control is provided by the heart exchanger. Cross-clamping the thoracic aorta limits perfusion to the lower part of the body. (From Starzl [219], with permission.)

Fig. 7. Contemporaneous host-versus-graft (HVG) and graft-versus-host (GVH) reactions in the two-way paradigm of transplantation immunology. Following the initial interaction, the maintenance of nonreactivity of each leukocyte population to the other is seen as a predominantly low grade stimulatory state that may wax and wane, rather than a deletional one.

Fig. 8.

Top panels. One-way paradigm in which transplantation is conceived as involving a unidirectional immune reaction: host-versus-graft (HVG) with whole organs (**left**) and graft-versus-host (GVH) with bone marrow or other lymphopoietic transplants (**right**). **Bottom panels.** Two-way paradigm in which transplantation is seen as a bidirectional and mutually canceling immune reaction that is predominantly HVG with whole organ grafts (**left**) and predominantly GVH with bone marrow grafts (**right**).

Fig. 9.

Continuum of chimerism from the observations of Owen in freemartin cattle to the discovery in 1992 of microchimerism in organ recipients.

Fig. 10.

Four events that occur in close temporal approximation when there is successful organ engraftment. **Top.** Double acute clonal exhaustion (1, 2) and subsequent maintenance clonal exhaustion (3). **Bottom.** Loss of organ immunogenicity due to depletion of the graft's passenger leukocytes (4).

Fig. 11.

Variable outcomes after infection with widely disseminated non-cytopathic viruses (or other microorganisms) and analogies (below individual graphs) to organ and bone marrow transplantation. The horizontal axis denotes time, and the vertical axis shows the viral load (V, solid line), and the host immune response (IR, dashed line).

Table 1

Direction of acceptable organ transfer when the donor and recipient have different ABO red blood cell types.

Transfer^a	Acceptability
O to non-O	Safe
Rh ⁻ to Rh ⁺	Safe
Rh ⁺ to Rh ⁻	Relatively safe
A to non-A	Dangerous
B to non-B	Dangerous
AB to non-AB	Dangerous

From Starzl [54].

^aFor organ transplantation, O is the universal donor and AB is the universal recipient. With the transplantation of bone marrow allografts or lymphoid-rich organ allografts (e.g., intestine or liver), enough anti-host isoagglutinins may be produced by the allograft to cause serious or lethal hemolysis in a significant number of cases (humoral graft-versus-host disease [55]). Consequently, the rules summarized in this table are fully applicable only with leukocyte-poor organs such as the kidney and heart (see section on Allograft Acceptance versus Acquired Tolerance).

Table 2

Nobel Prizes related to immunology/transplantation.

Year	Name	Accomplishment
1901	Emil Adolf Von Behring	Discovery of antibodies
1905	Heinrich Hermann Robert Koch	Cause and effect of microorganisms and infection
1908	Paul Ehrlich	Side chain (receptor) concept; champion of humoral immunity; antimicrobial therapy
	Ilya Metchnikoff	Champion of cellular immunity
1912	Alexis Carrel	Vascular surgery and transplantation
1919	Jules Bordet	Discovery of complement
1930	Karl Landsteiner	Discovered ABO blood group antigens
1960	Sir Frank MacFarlane Burnet	Clonal selection hypothesis
	Sir Peter Brian Medawar	Acquired transplantation tolerance
1972	Gerald M. Edelman	Characterized immunoglobulins
	Rodney R. Porter	Clarified structure of antibody molecule
1980	Baruj Benacerrat	Discovered immune response genes and collaborated in discovery of major histocompatibility complex (MHC) restriction
	Jean Dausset	Discovered first HLA antigen
	George Davis Snell	Discovery of MHC in mice
1984	Niels Kaj Jerne	Important immunologic hypotheses
	Georges J.F. Kohler	Hybridoma technology
	Cesar Milstein	Hybridoma technology
1985	Michael Stuart Brown and Joseph Leonard Goldstein	Hepatic control of cholesterol metabolism (with Goldstein) ^a
1987	Susumu Tonegawa	Discovered somatic recombination of immunologic receptor genes
1988	Gertrude Belle Elion and George Herbert Hitchings	Co-discovery (with Hitchings) of 6-mercaptopurine and azathioprine
1990	Joseph E. Murray	Kidney transplantation
	E. Donnall Thomas	Bone marrow transplantation
1996	Rolf Zinkernagel and Peter C. Doherty	Co-discovered (with Doherty) the role of MHC restriction in adaptive immune response to pathogens

From Schlessinger and Schlessinger [72], © 1991, with permission of Oryx Press, 4041 N. Central Avenue, Suite 700, Phoenix, AZ 85012; 800-279-6799.

^aProved with liver transplantation for indication of hypercholesterolemia [73, 74].

Table 3

Kidney transplantation with ≥ 6 months survival as of March 1963.

Case	City ^a	Refs.	Date	Donor	Survival (months) ^b
1	Boston	19, 86, 87	1/24/59	Fraternal twin	> 50
2	Paris	88, 89	6/29/59	Fraternal twin	> 45
3	Paris	90	6/22/60	Unrelated ^c	18 (died)
4	Paris	89	12/19/60	Mother ^c	12 (died)
5	Paris	90	3/12/61	Unrelated ^c	18 (died)
6	Paris	88	2/12/62	Cousin ^c	> 13
7	Boston	87, 111	4/5/62	Unrelated	10

^a Boston: J. E. Murray (cases 1, 7); Paris: J. Hamburger (cases 2, 4, 6) and R. Kuss (cases 3, 5).

^b The kidneys in patients 1, 2, and 6 functioned for 20.5, 25, and 15 years, respectively. Patient 7 rejected his graft after 17 months and died after return to dialysis.

^c Adjunct steroid therapy.

Table 4

Empiric therapeutic dogma of immunosuppression.

Ingredients of strategy	Baseline agent
Baseline therapy	Azathioprine ^a
Secondary adjustments of prednisone dose, or antilymphoid agents ^b	Cyclosporine
Case-to-case trial (and potential error) of weaning	Tacrolimus

^a Alone or with prophylactic prednisone. Equivalent results were obtained with cyclophosphamide instead of azathioprine [113, 114].

^b Initially used for prophylactic “induction” [115].

Table 5

Nonimmunologic profile.

Factor	Tacrolimus (FK 506)	Cyclosporin A
Nephrotoxicity	++ ^a	++
Neurotoxicity	+	+
Diabetogenicity	+	+
Growth effects		
Hirsutism	0	+++
Gingival hyperplasia	0	++
Facial brutalization	0	+
Hepatotrophic effects	++++	+++
Gynecomastia	0	+
Other metabolic effects		
Cholesterol increase	0 ^b	++
Uric acid increase	+?	++

Reprinted from Starzl et al. [214], copyright 1991, with permission from Elsevier Science.

+: best; ++++: worst (all dose-related).

^aLess hypertension.

^bDespite this observation in humans [161] Van Thiel observed an increase in cholesterol synthesis and serum concentration in rats (personal communication, August 1, 1990).

Table 6

Differences between conventional bone marrow and organ transplantation.

Factor	Bone marrow	Organ
Recipient cytoablation ^a	Yes	No
MHC compatibility	Critical	Not critical
Principal complication	GVHD	Rejection
Drug-free state	Common	Rare
Term for success	Tolerance	“Acceptance” ^b

GVHD: graft-versus-host disease; MHC: major histocompatibility complex.

^a All differences derive from this therapeutic step which in effect establishes an unopposed GVH reaction in the bone marrow recipient whose countervailing immune reaction is eliminated.

^b Also referred to as “operational tolerance.”

Table 7

Effectors involved in response to cytopathic parasites and discordant xenografts.

First line of defense
Interferons
Macrophages
$\gamma\delta$ T cells
Natural killer (NK) cells
B cells
Nonspecific or less specific effectors
Complement
Early interleukins
Phagocytes